AI in regulatory affairs: Transforming regulatory intelligence, submission planning, authoring, and commitment management

Regulatory affairs in life sciences is the governed interface between a product portfolio and health authorities. In pharma and medtech organizations, it connects regulatory intelligence, strategy, health authority interactions, submission planning, authoring, publishing, and query response. It also links license maintenance, labeling, commitments, and regulatory information management into one accountable chain of records.

External market estimates show why this operating layer receives sustained technology investment. Grand View Research estimated the global regulatory affairs market at USD 16.4 billion in 2024 and projected USD 27.2 billion by 2030 [1], while its RIM (Regulatory Information Management) systems estimate placed the global regulatory information management system market at USD 2.5 billion in 2025 with projected growth to USD 5.1 billion by 2033. [2]

Regulatory operations are also shaped by increasingly structured submission requirements. FDA identifies eCTD as the standard format for submitting applications, amendments, supplements and reports to CDER and CBER [3], ICH M8 defines the eCTD implementation framework [4], and EMA describes eCTD as the electronic submission format for CTD content from applicant to regulator. [5]

The challenge is that regulatory affairs teams must manage this structure across fragmented systems, strict submission formats, changing health authority expectations, and market-specific rules. A single regulatory event can affect dossier sections, RIM records, labeling, commitments, publishing sequences, and local maintenance actions. Manual review becomes difficult when teams must trace each decision back to approved sources, preserve submission timelines, and retain inspection-ready evidence.

This is where AI becomes relevant. Its value is not in replacing regulatory judgment, but in retrieving the right records, comparing them against current rules, identifying gaps or conflicts, and preparing review-ready packets for accountable RA roles. The opportunity is therefore best understood by decomposing the regulatory affairs operating model into functions, processes, and sub-processes. Each sub-process has its own starting artifact, source system, market rule, review boundary, output, and inspection evidence. Without that level of mapping, AI use cases remain too broad to govern or measure. For example, a model may prepare a Type IB versus Type II recommendation, but the GRL or CMC RA owner confirms the classification. It may draft a response to an RTQ, but the accountable reviewer owns the submitted position. It may identify a missing xEVMPD or UDI data field, but the RIM data steward confirms the record.

To define these opportunities precisely, this article maps regulatory affairs at the function, process, and sub-process levels. For each area, it identifies the relevant artifacts, systems, controls, accountable roles, human decision boundaries, and AI-enabled opportunities. This level of detail makes each use case more practical to design, govern, and measure.

How AI is transforming regulatory affairs operations
Why AI use cases in regulatory affairs must be mapped at the sub-process level
Regulatory affairs operating model and AI opportunity mapping across regulatory affairs processes
High-value AI use cases in regulatory affairs
How agentic AI works in regulatory affairs workflows
How to prioritize AI use cases in regulatory affairs
Governance, risk, and responsible AI in regulatory affairs
How ZBrain operationalizes AI use cases in regulatory affairs
Future of AI in regulatory affairs

How AI is transforming regulatory affairs operations

AI in regulatory affairs should be treated as an evidence and orchestration layer around controlled regulatory work, not as a replacement for regulatory judgment or health authority accountability. Regulatory affairs operates across a highly interconnected set of systems, records, decisions, and health authority requirements. A single post-approval CMC change can touch the QMS change record, RIM registrations, Module 3 content, variation classification rules, submission calendars, publishing sequences, commitments and local affiliate actions.

AI adds value when it retrieves and reconciles those records without weakening the authority of RIM, DMS, QMS, publishing, labeling or health authority correspondence systems. For example, a revised nitrosamine guideline should trigger more than a standalone summary. It should become an impact memo, affected-product list, market variation plan, eCTD content plan and reviewer-routed decision packet.

The role of AI becomes clearer when regulatory affairs activities are grouped into five areas: document review, evidence-based drafting, exception triage, knowledge retrieval, and workflow coordination.

Document-heavy work: eCTD sequences, Forms 356h and 1571, Module 2 summaries, Module 3 CMC sections, Q-Sub packages, EU MDR technical documentation, SPL XML files, and PMR or PMC dossiers can be checked for missing context and inconsistencies before review.
Narrative-heavy work: briefing documents, scientific advice positions, RTQ responses, variation rationales, label deviation justifications, and annual commitment reports can be drafted from approved sources while showing where evidence is limited.
Exception-heavy work: validation errors, missing ACKs, unresolved LOQ items, disputed variation classifications, late source documents, and inconsistent RIM records can be classified and prioritized for accountable review.
Knowledge-heavy work: health authority guidance, ICH step updates, EPAR precedent, CRL themes, QRD wording, SPL requirements, and post-approval change rules can be retrieved with citations and compared against product context.
Workflow-heavy work: submission calendars, dossier authoring tasks, query response workstreams, variation packages, label implementation, and commitment closure benefit when AI assembles the next packet and records the evidence trail.

The practical design rule is evidence before action. AI prepares, compares, classifies, drafts and monitors; named regulatory owners still confirm strategy, filings, commitments, label positions and submitted content.

Why AI use cases in regulatory affairs must be mapped at the sub-process level

Regulatory affairs work spans many connected but distinct responsibilities, from monitoring health authority updates to planning submissions, managing eCTD sequences, responding to agency questions, maintaining licenses, updating labels, and tracking commitments. Each area relies on different source records, systems, regulatory requirements, timelines, outputs, and accountable reviewers.

That variation makes broad functional framing too imprecise for AI design. “Automate regulatory affairs” is not a deployable use case because it does not define the trigger, source record, output, review boundary, or risk level. Regulatory intelligence triage starts with a health authority source and produces an impact memo. eCTD validation starts with a compiled sequence and produces an error queue. PMR closure starts with a commitment record and evidence package and produces a closure dossier. Each activity has a different risk profile, evidence requirement, and approval boundary, so each must be mapped separately before AI can be applied responsibly.

A better approach is to map AI use cases to the regulatory affairs operating model:

Function: a governed regulatory domain such as submission planning, publishing, labeling or RIM.
Process: a workflow area inside the function, such as eCTD validation, Type IA variation preparation or CCDS-to-local-label deviation tracking.
Sub-process: the atomic work activity with a starting artifact, source system, governing rule, accountable role, output artifact, health authority dependency, sequence impact and inspection evidence.
AI-enabled opportunity: a specific AI capability applied to that activity to produce a reviewable output, such as classifying eCTD validation errors or extracting commitments from an approval letter.

This level of mapping matters because regulatory work carries market-specific rules, authority clocks, system-of-record boundaries and inspection expectations. A model that helps with QRD template checks should not be evaluated like a model that proposes a CBE-30 classification or extracts a post-marketing commitment.

The same boundary discipline also prevents scope drift. Pharmacovigilance authors aggregate safety reports, while regulatory affairs submits them and manages the submission record. Labeling stays regulatory, covering CCDS, USPI, SPL, SmPC and PIL content.

For each use case, teams should define the trigger, source artifacts, systems involved, governing requirements, AI capability, expected output, accountable reviewer, exception path, downstream system impact, and evidence to be retained. This creates a sufficiently precise basis for solution design, risk assessment, validation, and performance measurement.

Build governed AI workflows across field service operations

Scale AI across work-order, dispatch, technician, parts, and billing workflows while maintaining human accountability for safety, coverage, customer commitments, and financial decisions.

Explore ZBrain Builder

Regulatory affairs operating model and AI opportunity mapping across regulatory affairs processes

The operating model below covers 11 core regulatory affairs functions from intelligence through RIM data governance. Each block anchors AI opportunity to artifacts, systems, standards, accountable RA roles, and a concrete human decision boundary.

Function 1: Regulatory intelligence and surveillance

This function turns health authority guidance, competitor decisions, and public precedent into a governed portfolio impact view. It sits before strategy and license maintenance because the same intelligence event can affect development assumptions, CMC commitments, labeling positions, and variation plans.

Teams involved: Regulatory intelligence analyst, global regulatory lead, CMC regulatory affairs manager, regulatory counsel, RIM data steward, and program or asset team leader run this function with escalation to the VP or head of regulatory affairs.

Key artifacts: FDA guidance docket alert, EMA or CHMP guideline revision, ICH step announcement, competitor approval package, EPAR, or CRL, regulatory intelligence impact assessment memo, product-by-market impact list, variation or strategy action register.

Systems involved: Regulatory intelligence platform, health authority websites, RIM system, document management system, submission archive, competitive intelligence repository, portfolio planning tool.

Regulatory and control considerations: FDA guidance process and CHMP guideline process, ICH guideline process, regulatory intelligence SOP, company variation classification playbook, 21 CFR 314.70.

Accountable roles: Regulatory intelligence analyst, global regulatory lead, CMC regulatory affairs manager, and head of regulatory affairs.

What AI helps with: Retrieval-grounded answering can compare a new guidance item with approved internal SOPs, prior impact memos, and affected dossier granules. Semantic similarity search, topic classification, and knowledge-graph traversal can map health authority language to products, markets, commitments, and open sequences.

What humans continue to own: The regulatory intelligence analyst confirms whether the source is applicable, the global regulatory lead accepts portfolio impact, and the head of regulatory affairs resolves disputed strategy or classification calls. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
Health authority surveillance	FDA guidance and docket monitoring	Retrieval-grounded answering compares new FDA guidance, draft guidance, docket updates, and enforcement or review communications against the regulatory intelligence SOP, product portfolio, and prior impact memos. Topic classification identifies the guidance domain, affected product types, submission implications, and implementation window.
	EMA and CHMP guideline monitoring	Semantic search and document-difference analysis compare new or revised EMA and CHMP guidelines with prior versions and approved internal positions. Change classification flags whether the update may affect dossier content, post-approval variations, labeling, or commitments.
	ICH step announcement tracking	Rule-based classification maps ICH step changes to affected development, quality, clinical, electronic submission, or post-approval change management workstreams. Retrieval-grounded summarization prepares a cited summary of the expected operational impact for regulatory intelligence analyst review.
	National agency circular monitoring	Multilingual document classification categorizes market-specific circulars and procedural updates, while entity extraction identifies relevant jurisdictions, organizations, products, deadlines, and local filing requirements. Market-impact mapping links the updates to local registrations, affiliate actions, and submission plans in RIM.
Competitive intelligence tracking	Competitor approval tracking	Named-entity recognition extracts product, indication, endpoint, population, approval condition, labeling position, and post-marketing obligation from approval packages, EPARs, and public review documents. Precedent retrieval links the above mentioned findings to comparable products, markets, and planned regulatory strategies.
	Complete response letter and deficiency tracking	Deficiency-theme classification extracts CMC, clinical, nonclinical, labeling, facility, safety, or statistical issues from public CRL records and related approval documents. Similarity search compares deficiency themes with the company’s active assets and open submission risks.
	Label and indication precedent monitoring	Semantic comparison analyzes competitor labels, SmPCs, USPI text, and indication language to identify claim patterns, limitations of use, safety wording, and population boundaries. Evidence ranking surfaces precedents relevant to planned labeling or response positions.
Public precedent analysis	Approval package and EPAR evidence review	Semantic search retrieves relevant prior approval packages, EPARs, assessment reports, labels, and review memos. Semantic comparison compares proposed regulatory positions with public precedent, surfacing aligned, divergent, and unsupported claims for global regulatory lead review.
	Review question and authority concern pattern analysis	Topic modeling and clustering identify recurring authority questions, objections, and evidence expectations across public review documents.
	Conditional approval and post-marketing obligation precedent review	Obligation extraction identifies approval conditions, specific obligations, PMRs, PMCs, due dates, evidence expectations, and closure patterns from public authority documents. Similarity search links the above-mentioned precedents to comparable assets or indications.
Portfolio impact triage	Product and market applicability screening	Knowledge-graph traversal maps a screened intelligence item to affected products, indications, markets, registrations, application types, and local affiliates in RIM. Entity resolution matches product names, application numbers, strengths, dosage forms, device identifiers, and market records to the correct regulatory entity.
	Dossier and submission impact assessment	AI identifies changes in regulatory guidance or precedent, maps them to affected CTD sections such as Module 2, Module 3, labeling, device technical documentation, or regional Module 1 content, and helps teams determine where updates, reviews, or supporting evidence may be required. Submission-calendar analysis identifies in-flight sequences, planned filings, and critical-path conflicts.
	Variation and supplement impact assessment	Rule-based classification applies the company variation playbook, ICH Q12, and 21 CFR 314.70 rules to recommend whether the change requires a PAS, CBE-30, CBE-0, annual report, Type IA, Type IB, or Type II action.
	Commitment and obligation impact screening	Obligation matching compares the intelligence item with open PMR, PMC, specific obligation, and PACMP records.
	Regulatory intelligence impact memo preparation	Retrieval-grounded generation drafts a cited impact memo covering source summary, affected products, affected markets, dossier sections, regulatory actions, owners, deadlines, uncertainties, and recommended escalation path. Evidence-linking preserves source URLs, source versions, retrieval dates, and reviewer disposition.
Governance and action tracking	Intelligence action register creation	Workflow orchestration converts approved impact memo outputs into owner-assigned action records for GRLs, CMC RA, labeling, RIM, publishing, or local affiliates. Deadline extraction identifies required completion dates, while dependency analysis flags actions at risk of delay because of missing inputs, unresolved dependencies, or overdue reviews.
Governance and action tracking	Source citation and inspection evidence retention	Evidence graph construction links each intelligence action to the original health authority source, internal SOP, affected product record, reviewer decision, and downstream action. Audit-trail generation records source evidence, AI outputs, reviewer actions, approvals, exceptions, and downstream updates to support inspection readiness.

Highest-value opportunities:Intelligence-to-impact portfolio triage is the strongest entry point because one guidance change can affect many products, markets, dossier granules, and commitments.

Example agentic workflow: Guideline revision to variation planning workflow

Trigger: An EMA guideline revision on nitrosamine impurity limits enters the regulatory intelligence queue.
Records retrieved: The agent retrieves affected registrations from the RIM system, current Module 3.2.S and 3.2.P specifications from the document management system, open sequences from the publishing tool, and related PMC entries.
Analysis prepared: The agent maps the guideline change to affected products, markets, dossier sections, impurity-related commitments, and planned submission sequences.
Output prepared: The agent drafts an impact memo and product-by-market variation plan with recommended regulatory actions and evidence links.
Human checkpoint: The regulatory intelligence analyst confirms applicability and evidence quality.
Approval and handoff: The global regulatory lead approves the plan, after which RIM records and authoring tasks are updated under existing governance.

Function 2: Regulatory strategy development

Regulatory strategy converts product evidence, target claims, and market intent into a filing path and authority engagement plan. It feeds health authority interactions, submission planning, authoring priorities, and global registration sequencing.

Teams involved: Global regulatory lead, VP or head of regulatory affairs, regulatory counsel, program or asset team leader, CMC regulatory affairs manager, and regulatory affairs country managers own the strategy process.

Key artifacts: Target product profile, development plan, designation eligibility evidence, breakthrough therapy eligibility packet, global submission sequence, reference-country rationale, and regulatory risk register.

Systems involved: RIM, clinical document repository, regulatory strategy repository, portfolio planning system, agency precedent repository, and meeting management tool.

Regulatory and control considerations: FDA expedited programs guidance, orphan drug designation rules, and scientific advice procedures, ICH E6(R3), ICH Q8 to Q12, and local filing frameworks.

Accountable roles: Global regulatory lead, regulatory counsel, program or asset team leader, and head of regulatory affairs.

What AI helps with: Evidence retrieval, eligibility classification, and scenario simulation can connect product claims, endpoint evidence, CMC readiness, and market sequencing assumptions. Natural-language generation can draft strategy options while exposing missing evidence and authority dependencies.

What humans continue to own: The global regulatory lead owns filing strategy, designation choices, reference-country logic, and risk acceptance. Regulatory counsel and the head of regulatory affairs confirm legal or high-impact strategic positions. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
Regulatory positioning	Target claim annotation	Retrieval-grounded answering links target claims, indications, populations, endpoints, comparators, benefit-risk assumptions, and proposed label language to precedent labels, EPARs, FDA review documents, and prior health authority feedback. Evidence extraction creates a regulatory annotation summary for global regulatory lead review.
	Endpoint and comparator evidence mapping	Semantic search can help regulatory teams find comparable precedents by retrieving relevant endpoint choices, comparator expectations, and population definitions from prior authority feedback, public assessment reports, and approved product labels. Natural-language inference flags where the proposed TPP differs from precedent or lacks supporting evidence.
	Label ambition and evidence alignment	Claim-to-evidence mapping links proposed label claims to supporting clinical, nonclinical, and CMC evidence, identifying gaps or inconsistencies for regulatory review. Contradiction detection surfaces claims that are stronger than the evidence package or inconsistent with prior authority positions.
Designation planning	Orphan drug designation assessment	Rule-based classification compares disease prevalence, medical plausibility, product rationale, and proposed indication against orphan designation criteria. Precedent retrieval identifies comparable orphan designation and approval patterns for GRL review.
	Fast track and breakthrough therapy assessment	Criteria-based eligibility assessment evaluates the product evidence against requirements related to serious conditions, unmet medical need, available therapies, preliminary clinical evidence, and potential improvement over existing treatments. Evidence synthesis assembles and cites the evidence supporting each designation criterion, while highlighting gaps and contradictory findings for regulatory review.
	Sakigake opportunity assessment	Retrieval-grounded comparison maps product evidence, unmet need, early clinical data, and proposed development plan against Sakigake expectations. Scenario analysis evaluates potential submission pathways to identify timeline implications, evidence gaps, and likely health authority questions.
	Designation package readiness review	Document intelligence checks whether the designation request contains required rationale, evidence, references, product details, and proposed indication language. Completeness assessment evaluates the package against defined content and evidence requirements, identifying missing or unresolved elements in a readiness report for GRL review.
Global filing pathway planning	Reference country strategy development	Scenario simulation models how different reference-country choices, reliance pathways, evidence requirements, approval dependencies, and submission sequences could affect regulatory timelines and outcomes. Knowledge-graph traversal links country choices to downstream registration and local affiliate actions.
	Global submission sequencing	Constraint-based optimization recommends a submission sequence that balances review timelines, CMC and manufacturing readiness, clinical evidence availability, labeling dependencies, and market priorities.
	Market-specific filing pathway assessment	Rule-based classification maps each target market to the relevant filing route, submission type, reliance option, device pathway, or local procedural requirement. Retrieval-grounded analysis identifies market-specific documents, forms, translation requirements, and local review dependencies that could affect filing readiness.
	Reference label and local label sequencing	Semantic comparison evaluates how USPI, SmPC, CCDS, and local labeling dependencies may affect submission timing. Dependency analysis identifies where label negotiations or local deviations could delay filings.
Regulatory risk management planning	Health authority feedback integration	Semantic comparison identifies agreements, differences, and unresolved inconsistencies across prior meeting minutes, scientific advice, Q-Sub feedback, written responses, and internal development plans. Obligation extraction identifies authority commitments, unresolved questions, and required follow-up actions.
	Evidence gap and unsupported-claim detection	Anomaly detection and contradiction checking identify claims, endpoints, comparators, CMC assumptions, or device performance statements that lack supporting evidence.
	CMC regulatory risk assessment	Knowledge-graph traversal links formulation, manufacturing process, control strategy, specifications, stability, site readiness, and planned post-approval changes to expected dossier sections and authority questions. Risk scoring ranks CMC gaps by their potential impact on submission readiness, regulatory acceptability, and review timelines for CMC regulatory affairs review.
	Device regulatory pathway risk assessment	Classification and predicate or equivalence analysis compare device features, intended use, indications, risk class, clinical evidence, and technical documentation readiness.
	Regulatory risk register and mitigation planning	Predictive analytics and dependency mapping combine evidence gaps, authority feedback, planned filings, manufacturing readiness, labeling issues, and market dependencies into a regulatory risk register. Natural-language generation prepares proposed mitigation actions.

Highest-value opportunities: Designation strategy assessment and global sequencing are high leverage because they influence development evidence, authority engagement, and market entry logic before authoring begins.

Example agentic workflow: Breakthrough therapy readiness workflow

Trigger: A global regulatory lead requests a breakthrough therapy readiness screen for a product with early clinical evidence.
Records retrieved: The agent retrieves the target product profile, study summaries, public designation precedents, prior health authority feedback, and approved internal designation criteria.
Analysis prepared: The agent compares unmet need, seriousness of condition, available therapy, preliminary clinical evidence, and expected development implications against designation requirements.
Output prepared: The agent drafts a comparative eligibility packet with evidence links, open questions, and recommended next steps.
Human checkpoint: The global regulatory lead reviews and approves the strategic recommendation.
Escalation: Any legal interpretation or disputed eligibility position is escalated to regulatory counsel.

Function 3: Health authority interaction management

Health authority interaction management converts strategic questions into controlled requests, briefing packages, meeting records, and commitments. It creates the evidence trail that connects FDA, EMA, national authority, or device feedback to the product plan.

Teams involved: Global regulatory lead, regulatory medical writer, regulatory operations manager, regulatory counsel, CMC regulatory affairs manager, and regulatory affairs country manager coordinate this function.

Key artifacts: Pre-IND or Type B/C/D meeting request, protocol assistance request, Q-Sub package, briefing document, agency agenda, meeting minutes, and commitment log.

Systems involved:Meeting management tool, document management system, RIM, submission archive, health authority correspondence mailbox, and publishing tool.

Regulatory and control considerations: FDA PDUFA formal meeting guidance, FDA Q-Submission guidance, internal meeting SOP, and commitment-capture SOP.

Accountable roles: Global regulatory lead, regulatory medical writer, regulatory operations/publishing manager, and regulatory counsel.

What AI helps with: Document intelligence can test briefing packages for completeness, question-answer alignment, and evidence citations. Retrieval-grounded summarization and contradiction detection can reconcile agency minutes, sponsor minutes, and internal action records.

What humans continue to own: The global regulatory lead owns the questions, positions, commitments, and final response to authority feedback. Regulatory counsel confirms high-risk interpretations, and regulatory operations controls submission routing. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
FDA meeting management	Pre-IND meeting request preparation	Schema validation checks whether the meeting objective, product context, development issue, proposed questions, and requested meeting type align with FDA formal meeting expectations. Retrieval-grounded generation prepares a meeting request outline with required background elements for global regulatory lead review.
	Type B meeting package planning	Question classification maps pre-IND, end-of-phase, pre-NDA, pre-BLA, or other Type B questions to the relevant clinical, nonclinical, CMC, statistical, or regulatory evidence. Evidence mapping identifies missing source documents before drafting the briefing package.
	Type C and Type D meeting request preparation	Topic classification categorizes regulatory questions by scope and complexity to distinguish strategic issues from focused questions that may be appropriate for a Type C or Type D meeting. Retrieval-grounded answering compares the proposed questions with prior FDA feedback and internal development records, preparing a meeting request rationale.
	FDA background package outline creation	Document intelligence maps meeting objectives, questions, sponsor positions, data summaries, and appendices to the expected background package structure. Completeness scoring rates each proposed question and position against defined readiness criteria, highlighting missing rationale or evidence, unclear questions, and unsupported positions before authoring begins.
Device health authority interaction management	FDA Q-Submission package planning	Document classification maps device questions, intended use, proposed testing, predicate or clinical context, and attachments to Q-sub package expectations. Completeness checking prepares a package-readiness report before global regulatory lead approval.
	Pre-sub feedback question refinement	Natural-language classification separates regulatory, clinical, performance testing, biocompatibility, software, cybersecurity, human factors, and predicate questions. Retrieval-grounded generation rewrites questions into reviewable form while preserving the sponsor’s position and evidence citations.
	Q-sub feedback tracker creation	Obligation extraction captures FDA written feedback, meeting outcomes, follow-up requests, and unresolved questions from Q-sub correspondence. Workflow orchestration converts confirmed feedback into owner-assigned actions for device regulatory, clinical, quality, or engineering teams.
Briefing document development	Briefing document authoring	Retrieval-grounded generation drafts background, rationale, company position, question framing, and supporting summaries from approved clinical, nonclinical, CMC, device, and regulatory source documents. Citation checking links each claim to controlled evidence and flags unsupported statements.
	Question-to-evidence alignment	Evidence retrieval maps each health authority question to the source documents, data summaries, prior feedback, and proposed company position needed to support it. Contradiction detection flags where the proposed position conflicts with the dossier, prior minutes, or approved internal strategy.
	Cross-functional input consolidation	Entity extraction pulls specific terms or attributes from comments, while workflow classification categorizes and routes them. Neither directly performs consolidation. Version comparison identifies conflicting inputs, unresolved reviewer comments, and late dependencies before final package review.
Health authority correspondence management	Meeting agenda and logistics tracking	Deadline extraction and workflow monitoring track request submission, FDA or EMA response dates, package due dates, meeting dates, agenda updates, and owner actions. Predictive analytics flags schedule risk when source documents or approvals are late.
Health authority correspondence management	Agency response and preliminary comment analysis	Semantic summarization extracts agency preliminary comments, concerns, requests for clarification, and suggested agenda changes. Topic clustering groups comments by clinical, CMC, nonclinical, statistical, labeling, device, or procedural issue for GRL review.
Meeting outcome management	Meeting minutes reconciliation	Semantic comparison compares agency minutes, sponsor minutes, internal notes, and action trackers to identify discrepancies in advice, commitments, assumptions, and unresolved questions.
	Commitment and action capture	Obligation extraction identifies commitments, follow-up actions, owners, deadlines, affected dossier sections, and submission impacts from final minutes of meetings or written advice. Entity linking maps each commitment to RIM records, submission plans, and the commitment register.
	Health authority feedback review	Natural-language inference compares final authority feedback with the current regulatory strategy, TPP, development plan, risk register, and submission calendar. Impact classification identifies whether the feedback changes filing sequence, evidence generation, labeling strategy, CMC plans, or future meeting needs.
	Inspection-ready evidence retention	Evidence graph construction links meeting requests, briefing documents, submitted packages, authority meeting minutes, sponsor notes, commitments, reviewer decisions, and follow-up actions. Audit-log generation preserves source versions, approval history, and reviewer disposition for inspection readiness.

Highest-value opportunities: Meeting minutes reconciliation and commitment capture is a strong first project because authority feedback must be translated accurately into accountable action without losing context.

Example agentic workflow: Health authority minutes-to-commitment workflow

Trigger: FDA Type C meeting minutes arrive after a discussion on CMC comparability.
Records retrieved: The agent retrieves agency minutes, sponsor notes, prior briefing materials, Module 3 sections, the submission calendar, and the existing commitment register.
Analysis prepared: The agent compares agency minutes with sponsor notes, identifies differences, extracts commitments, and maps each commitment to affected CMC sections, owners, deadlines, and submission dependencies.
Output prepared: The agent drafts a commitment log with source references, unresolved interpretation points, and recommended owner assignments.
Human checkpoint: The global regulatory lead confirms each commitment and owner assignment.
Escalation: Any disputed interpretation or high-risk commitment language is escalated to regulatory counsel.

Function 4: Submission planning and dossier management

Submission planning converts strategy into an executable dossier plan, document inventory, and critical path. It sits between authority strategy and authoring, and it determines whether teams know which granules, forms, and source documents are required for each market.

Teams involved: Regulatory operations/publishing manager, global regulatory lead, regulatory medical writer, CMC regulatory affairs manager, RIM data steward, and regulatory affairs country managers run this function.

Key artifacts: eCTD content plan, granule-level inventory, submission calendar, CTD gap report, source document readiness tracker, Form 356h, 1571, or 3674 checklist, and device submission inventory.

Systems involved: RIM, publishing tool, document management system, submission planning tool, source document repository, and project management system.

Regulatory and control considerations: ICH M4, FDA eCTD guidance, ICH M8, regional Module 1 requirements, FDA forms guidance, medical device submission guidance, and internal submission planning SOP.

Accountable roles: Regulatory operations/publishing manager, global regulatory lead, CMC regulatory affairs manager, and RIM data steward.

What AI helps with: Ontology mapping, schema validation, and critical-path analysis can connect CTD expectations to actual source documents, planned sequences, forms, and owner assignments. Predictive analytics can identify likely blockers from historical readiness patterns.

What humans continue to own: Regulatory operations team owns the submission plan and publishing readiness; the GRL confirms regulatory content scope; functional owners attest source-document readiness. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
Submission scope definition	Submission type and application lifecycle mapping	Rule-based classification maps the approved filing strategy to submission type, application type, lifecycle event, market, procedure, and required regional content. Ontology mapping links the filing scope into CTD modules, regional Module 1 items, application forms, sequence type, and expected dossier granules.
Submission scope definition	Product, market, and procedure scope confirmation	Entity resolution reconciles product name, application number, strength, dosage form, device identifier, market, procedure, and local affiliate data across RIM and the submission planning tool. Anomaly detection flags mismatches that could affect the content plan or regional Module 1 package.
eCTD planning	eCTD content plan creation	Ontology mapping links the submission type, market, application lifecycle, and procedure to the applicable CTD sections, regional Module 1 requirements, and document placeholders, while schema validation verifies that the dossier structure is complete and correctly configured.
	Document-to-granule mapping	Document classification maps each planned document to the correct CTD section, lifecycle operator, owner, source system, and expected publishing status. Completeness validation identifies missing granules, duplicate placeholders, and sections with unclear ownership.
	Regional Module 1 requirement mapping	Retrieval-grounded checklisting compares the target market and procedure with regional Module 1 expectations, forms, administrative documents, product information, cover letters, and country-specific attachments. Gap detection flags missing regional content before authoring or publishing begins.
	Cross-reference and dependency planning	Knowledge-graph traversal maps dependencies among Module 2 summaries, Module 3 CMC sections, clinical summaries, nonclinical summaries, labeling, forms, appendices, and regional documents. Dependency analysis identifies sections that cannot be finalized until upstream evidence or approvals are complete.
Dossier inventory management	Dossier document owner assignment	Workflow classification assigns planned granules to regulatory medical writer, CMC RA, regulatory operations, labeling, QA, local affiliate, or functional source-document owners based on document type and market. Workload analysis highlights overallocated owners and unresolved assignments.
Dossier inventory management	Version and lifecycle state tracking	Version comparison reconciles draft, in-review, approved, superseded, and published document states across DMS, RIM, and the publishing tool. Status classification flags stale documents, unapproved versions, and documents not aligned with planned sequence timing.
Submission calendar management	Submission calendar creation	Critical-path analysis converts target submission date, health authority meeting dates, document due dates, quality-control cycles, publishing windows, validation cycles, gateway transmission steps, and approval milestones into a submission calendar.
	Critical-path and bottleneck monitoring	Dependency and critical-path analysis maps document, review, approval, publishing, validation, and gateway dependencies to identify those that could delay the planned submission date. Risk scoring prioritizes late or blocked items for GRL and regulatory operations review.
	Health authority milestone alignment	Deadline extraction maps planned health authority meetings, PDUFA or regional procedure dates, response windows, clock-stop periods, and submission commitments to the calendar. Conflict detection flags overlaps between authority deadlines and internal document readiness.
	In-flight sequence conflict review	Submission-calendar analysis compares planned sequences, variations, supplements, responses, labeling updates, and annual reports across the same application or market. Conflict detection identifies sequence collisions, dependency conflicts, and resource constraints.
Dossier gap analysis	CTD expectation gap analysis	Retrieval-grounded checklisting and document classification compare planned dossier granules with ICH M4, ICH M8, FDA eCTD expectations, and regional Module 1 rules.
	Market-specific dossier gap review	Rule-based checklisting compares market requirements, procedure type, application forms, labeling documents, translations, legal documents, device technical documentation, and local affiliate requirements against the planned dossier inventory. Gap scoring assigns each missing item an impact score based on regulatory criticality, dependency risk, and potential effect on submission readiness, enabling teams to prioritize remediation.
	Form and administrative document readiness review	Schema validation checks forms such as Form 356h, Form 1571, Form 3674, cover letters, application forms, declarations, and administrative documents for required fields, metadata consistency, and supporting attachments. Entity resolution flags mismatches between forms, RIM records, and dossier documents.
	Cross-reference and citation integrity review	Link analysis checks cross-references among Module 2, Module 3, clinical, nonclinical, labeling, appendices, and regional documents. Contradiction detection identifies unsupported references, inconsistent document titles, and citations pointing to unapproved or missing source documents.
Source document readiness management	Source document readiness tracking	Entity resolution and status reconciliation match related records across DMS, project management, and RIM systems, align their workflow states, and flag status discrepancies affecting submission readiness.
	Functional source evidence completeness review	Document intelligence checks whether required clinical, nonclinical, CMC, device, labeling, biostatistics, quality, and administrative evidence is present for the planned dossier sections. Completeness validation identifies evidence gaps before authoring teams finalize dossier text.
	Review cycle and approval dependency monitoring	Workflow monitoringtracks document review cycles, reviewer comments, approval routing, quality-control checks, and pending signatures. Predictive analytics identifies documents likely to miss readiness dates based on review history and current status.
	Publishing handoff readiness assessment	AI-assisted lifecycle-state reconciliation checks whether approved documents, metadata, file formats, document titles, versions, and ownership status are ready for publishing. Validation pre-checking flags files likely to create eCTD compilation or validation issues.

Highest-value opportunities: Dossier gap analysis is high value because it detects missing CTD content before expensive publishing cycles or health authority validation failures.

Example agentic workflow: Dossier gap-to-authoring plan workflow

Trigger: The global regulatory lead approves an MAA filing plan.
Records retrieved: The agent retrieves the approved filing strategy, product and market scope, planned submission timeline, RIM records, document inventory, and applicable ICH M4.
Analysis prepared: The agent maps the planned dossier against CTD structure, regional Module 1 expectations, required forms, source documents, and document-to-granule dependencies.
Output prepared: The agent prepares a CTD gap report, document-to-granule map, owner assignments, and authoring-readiness exceptions.
Human checkpoint: Regulatory operations teams review and confirm the dossier plan and gap report.
Handoff: Functional authors accept assigned granules and update authoring timelines under the submission plan.

Function 5: Dossier authoring

Dossier authoring converts approved scientific, clinical, nonclinical, CMC, and device source evidence into regulated narrative sections. AI can support this work by producing evidence-linked drafts from controlled sources, while regulatory authors and subject-matter experts remain responsible for the accuracy, interpretation, and approval of the content.

Teams involved: Regulatory medical writer, CMC regulatory affairs manager, global regulatory lead, quality assurance liaison, regulatory counsel, and device regulatory specialists participate in this function.

Key artifacts: Quality overall summary Module 2.3, nonclinical overview Module 2.4, clinical overview Module 2.5, Module 3 CMC section, response document, and source evidence package.

Systems involved: Document management system, clinical, nonclinical, and CMC repositories, QMS, RIM, device technical documentation repository, and submission archive.

Regulatory and control considerations: ICH M4, ICH M4Q, ICH Q8 to Q12, ICH E6(R3),internal medical writing and document control SOPs.

Accountable roles: Regulatory medical writer, CMC regulatory affairs manager, global regulatory lead, and quality assurance liaison.

What AI helps with: Retrieval-grounded generation, document intelligence, contradiction detection, and citation verification can draft regulated narratives from approved evidence. Semantic consistency checking can compare claims across Module 2 summaries, Module 3 CMC content, labeling, and response documents.

What humans continue to own: Regulatory authors own the dossier narrative, interpretation, and section-level quality, while SMEs confirm the accuracy and completeness of scientific, clinical, nonclinical, CMC, and device evidence. AI can retrieve evidence, draft, and revise content, but it does not make regulatory judgments, approve content, or attest readiness.

Process	Sub-process	AI-enabled opportunities
Module 2 summary authoring	Quality overall summary, Module 2.3 drafting	Retrieval-grounded generation drafts QOS sections from approved Module 3 source content, specifications, manufacturing process descriptions, control strategy, validation evidence, and stability data. Citation verification links each quality statement to controlled source evidence and flags unsupported claims.
	Nonclinical overview, Module 2.4 drafting	Evidence extraction identifies pharmacology, pharmacokinetic, toxicology, safety pharmacology, and study-summary evidence from approved nonclinical reports. Natural-language generation prepares a source-linked overview while contradiction detection flags inconsistencies across study summaries and proposed risk language.
	Clinical overview, Module 2.5 drafting	Retrieval-grounded generation drafts clinical overview sections from approved clinical study reports, integrated summaries, endpoint evidence, safety findings, benefit-risk rationale, and proposed labeling claims. Claim-evidence matching identifies statements that lack source support or diverge from the target label.
	Cross-summary consistency review	Semantic comparison evaluates Module 2.3, 2.4, 2.5, labeling, response documents, and prior authority feedback. Contradiction detection surfaces inconsistent claims, terminology drift, unsupported conclusions, and mismatched benefit-risk statements for regulatory medical writer review.
	Claim-to-source validation	Citation verification maps every key claim, table value, endpoint, specification, study conclusion, and regulatory position to an approved source document. Evidence graph construction preserves traceable relationships among the dossier narrative, source report, document version, and reviewer disposition.
Module 3 CMC authoring	Drug substance section drafting	Structured data extraction pulls substance characterization, manufacturer information, control strategy, specifications, analytical procedures, validation evidence, reference standards, and stability data from approved CMC records. Retrieval-grounded generation uses the extracted evidence to prepare draft Module 3.2.S content for CMC regulatory affairs review.
	Drug product section drafting	Document intelligence extracts formulation, manufacturing process, batch formula, process controls, container closure, specifications, analytical methods, validation, and stability evidence. Semantic consistency checking compares draft Module 3.2.P content against approved source records and registered details.
	Control strategy and specification update	Structured data extraction captures approved specifications, analytical methods, acceptance criteria, control strategy, and change-control records from existing Module 3 content. Rule-based comparison flags whether the update may affect post-approval change classification or registered commitments.
	Manufacturing process lifecycle update	Semantic difference compares approved manufacturing process changes, site changes, batch-size changes, validation updates, and process-control changes with the current Module 3 narrative. Natural language generation prepares lifecycle update text and highlights affected sections, tables, and appendices.
	Stability and shelf-life narrative update	Time-series data extraction and table validation compare approved stability summaries, shelf-life commitments, storage conditions, and post-approval stability protocols with existing dossier text. Consistency checking flags mismatches between stability data, labeling storage statements, and registered commitments.
	PACMP and post-approval change alignment	Knowledge-graph traversal links CMC changes to PACMP commitments, prior approvals, Module 3 sections, registered details, and planned variations. Change-impact analysis identifies affected dossier content, commitments, markets, and filing plans and prepares a cited impact assessment for CMC regulatory affairs review.
	Risk management and clinical evaluation consistency review	Semantic consistency checking compares the risk management file, clinical evaluation report, PMS evidence, labeling, IFU, and technical documentation. Contradiction detection flags inconsistent intended use, residual risk statements, benefit-risk claims, and evidence gaps.
Response document authoring	Health authority question interpretation	Natural-language classification categorizes each information request, RTQ, or list-of-questions item by clinical, nonclinical, CMC, labeling, device, statistical, procedural, or administrative domain. Deadline extraction identifies response dates and procedural milestones, while rules-based routing assigns each question to the appropriate response owner and reviewer.
	Evidence retrieval for response drafting	Semantic search retrieves relevant dossier sections, source reports, prior responses, authority minutes, labeling text, CMC records, and commitments tied to the question. Evidence ranking prioritizes authoritative and directly relevant sources while surfacing conflicting or incomplete evidence for response-owner review.
	Draft response generation	Natural language generation drafts concise response text, rationale, data summaries, tables, and proposed commitments from approved evidence. Citation verification links each answer element to source documents and flags unsupported statements.
	Answer-evidence alignment review	Answer-evidence alignment checks whether each response directly addresses the authority question and whether the cited evidence supports the answer. Contradiction detection identifies conflicts with the dossier, label, prior authority feedback, registered details, or earlier responses.
	Response package readiness check	Schema validation checks required structure, file formats, metadata, and publishing conventions, while completeness assessment verifies the presence of response sections, attachments, citations, and required approvals. Workflow monitoring flags late inputs, unresolved comments, and approval blockers before submission handoff.

Highest-value opportunities: Module 3 lifecycle authoring and response document authoring are high value because they are evidence-heavy, deadline-driven, and tightly linked to post-approval change control.

Example agentic workflow: CMC change-to-Module 3 update workflow

Trigger: A CMC change control record is approved for a specification update.
Records retrieved: The agent retrieves the prior Module 3 section, approved specification, validation report, registered details, related stability evidence, and PACMP context.
Analysis prepared: The agent compares the approved CMC change with existing Module 3 text, tables, registered information, and related commitments.
Output prepared: The agent drafts the affected Module 3 updates, identifies impacted sections, links supporting evidence, and flags any commitment conflicts.
Human checkpoint: The CMC regulatory affairs manager reviews and confirms the technical and regulatory accuracy of the proposed content.
Handoff: The confirmed content moves to document control for approval and downstream submission planning.

Accelerate AI Solutions Development

Build fully functional solutions from your high-value use cases, based on specific operational needs and enterprise context.

Book a Customized Demo

Function 6: Publishing and submission operations

Publishing and submission operations turn approved content into technically valid, transmitted, and acknowledged regulatory sequences.

Teams involved: Regulatory operations/publishing manager, publishing specialists, RIM data steward, global regulatory lead, and regulatory affairs country managers run this function.

Key artifacts: eCTD sequence with index.xml backbone, regional Module 1, hyperlink and bookmark report, eCTD validation report, FDA ESG ACK1, ACK2, ACK3, or ACK4, CESP receipt, and sequence lifecycle record.

Systems involved: Publishing tool, eCTD validator, FDA ESG or ESG NextGen, EMA gateway, CESP, RIM, submission archive.

Regulatory and control considerations: FDA eCTD guidance, ICH M8, FDA eCTD v4.0 standards, FDA ESG acknowledgment process, and internal publishing SOP.

Accountable roles: Regulatory operations/publishing manager, RIM data steward, and global regulatory lead.

What AI helps with: Technical validation, classification, hyperlink anomaly detection, and lifecycle-sequence reconciliation can reduce rework before gateway submission. Process mining can compare ACK status, sequence metadata, and RIM records to identify blocked or misfiled submissions.

What humans continue to own: The regulatory operations team approves final sequence release and confirms the correct gateway, region, and application lifecycle action. The GRL confirms content readiness and filing intent. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
eCTD compilation	Approved document intake for publishing	Document classification verifies that approved dossier documents match the content plan, CTD section, lifecycle event, regional Module 1 requirement, and submission type. Document-status reconciliation flags documents that are unapproved, superseded, incorrectly titled, or missing from the publishing package.
	eCTD sequence assembly	Document structure parsing maps approved documents to the correct eCTD hierarchy, leaf titles, file names, lifecycle operators, and sequence metadata. Schema validation checks whether the compiled package aligns with ICH M8, FDA eCTD specifications, EMA eCTD specifications, and regional Module 1 rules.
	Regional Module 1 assembly	Completeness checking evaluates administrative forms, cover letters, product information, application metadata, declarations, and regional attachments against market-specific Module 1 requirements. Gap detection flags missing or inconsistent regional content before validation.
	Lifecycle operator assignment	AI-assisted classification recommends new, replace, append, delete, or other lifecycle operators based on the prior sequence, current document state, and planned regulatory activity. Sequence history reconciliation flags operator conflicts that could break lifecycle continuity.
	File naming and metadata normalization	Named entity extraction and metadata validation compare document titles, file names, application numbers, product names, sequence numbers, submission type, and market metadata across RIM, DMS, and the publishing tool. Anomaly detection flags mismatches before technical validation.
Hyperlinking and navigation	Bookmark and hyperlink verification	Hyperlink anomaly detection verifies internal links, external references, bookmarks, tables of contents, cross-document references, and PDF navigation. Link analysis flags broken links, circular references, orphan bookmarks, and references pointing to outdated documents.
	Cross-reference integrity review	Cross-reference resolution matches citations in Module 2, Module 3, clinical, nonclinical, labeling, appendix, and regional documents with their intended dossier sections, tables, figures, and source files. Contradiction detection identifies references to missing sections, mismatched table numbers, or unapproved source documents.
	PDF technical readiness review	Document intelligence checks file format, page orientation, readability, bookmarks, OCR status, embedded fonts, page size, and security settings. Validation pre-checking identifies documents likely to trigger eCTD validation warnings or publishing rework.
Technical validation	eCTD validation error classification	Validation-error classification groups errors and warnings by file, lifecycle operator, XML metadata, regional Module 1 field, hyperlink, format, checksum, and folder structure. Root-cause clustering groups related findings and prepares a prioritized remediation queue for regulatory operations review.
	Validation warning impact assessment	Rule-based severity scoring distinguishes critical errors, fix-before-submission warnings, acceptable warnings, and reviewer-noted exceptions. Evidence linking connects each validation finding to the relevant rule, affected file, proposed correction, and reviewer decision.
	Repeat-error pattern detection	Pattern analysis compares current validation findings with historical sequence errors by product, market, submission type, publisher, document source, and tool version. Predictive analytics identifies recurring causes of publishing rework and likely future validation blockers.
	Validation remediation tracking	Workflow orchestration routes validation fixes to publishing, authoring, RIM, labeling, or local affiliate owners. Status classification tracks open, corrected, retested, accepted, or escalated validation findings before sequence release.
Submission transmission	Gateway and channel selection	Rule-based channel selection maps application type, market, procedure, submission format, and regional requirement to FDA ESG or ESG NextGen, EMA gateway, CESP, CDRH portal, or other approved channel.
	Transmission metadata preparation	Entity resolution reconciles application number, sequence number, submission type, product, sponsor, market, procedure, contact, and gateway metadata across RIM, publishing, and submission archive records. Schema validation flags metadata mismatches before release.
	Release package preparation	Retrieval-grounded generation prepares a release packet containing validation status, sequence metadata, transmission route, open warnings, source documents, approval status, and reviewer sign-offs. Completeness scoring evaluates the packet against defined release requirements and highlights missing approvals, unresolved exceptions, or incomplete evidence for human review.
	Submission transmission record creation	Automated record creation captures the submitted package identifier, gateway transaction ID, transmission timestamp, application metadata, responsible publisher, and release approval in the submission archive. Audit-log generation preserves transmission evidence in the submission archive.
ACK and receipt monitoring	FDA ACK1, ACK2, ACK3, and ACK4 interpretation	Event classification interprets ACK1, ACK2, ACK3, or ACK4 messages and maps each status to upload, center transmission, center response, or follow-up action. Anomaly detection flags missing, delayed, failed, or inconsistent acknowledgments.
	Sequence lifecycle status reconciliation	RIM reconciliation compares gateway acknowledgments, publishing records, sequence metadata, submission archive entries, and application lifecycle state. Entity resolution flags mismatched sequence numbers, submission dates, procedure types, or lifecycle statuses.
	ACK exception routing and closure	Workflow orchestration routes ACK failures, missing receipts, or mismatched lifecycle records to regulatory operations, RIM data steward, local affiliate, or technical support owners. Audit-log generation records exception cause, correction, reviewer disposition, and final lifecycle status.
Submission archive management	Submission archive evidence retention	Evidence graph construction links compiled sequence, validation report, release approval, transmission record, ACK messages, reviewer decisions, and RIM lifecycle updates. Inspection-readiness scoring evaluates the archive against defined evidence requirements and identifies missing, unlinked, or incomplete records.
Submission archive management	Sequence lifecycle history review	Knowledge graph traversal connects prior sequences, current sequence, lifecycle operators, replaced documents, related variations, supplements, responses, and annual reports. Semantic consistency checking flags lifecycle breaks or unresolved document history issues.

Highest-value opportunities: Validation error triage and ACK monitoring are strong entry points because they are technical, repeatable, and bounded by regulatory operations review.

Example agentic workflow: eCTD validation-to-ACK monitoring workflow

Trigger: A validated NDA supplement sequence is ready for FDA ESG transmission.
Records retrieved: The agent retrieves the compiled eCTD sequence, validation report, lifecycle operator history, regional Module 1 metadata, planned application action, RIM record, and submission calendar.
Analysis prepared: The agent checks lifecycle operators, validation warnings, sequence metadata, regional requirements, and alignment with the planned application action.
Output prepared: The agent prepares a submission release packet with validation status, open warnings, metadata checks, evidence links, and release readiness notes.
Human checkpoint: Regulatory operations team reviews the release packet and confirms the sequence for transmission.
Handoff: After regulatory operations teams release the sequence, the agent monitors ACK messages and prepares RIM reconciliation updates for review.

Function 7: Health authority query and response management

Health authority query and response management converts IRs, RTQs, lists of questions, and approval-letter conditions into coordinated response work. The function sits under strict clocks and depends on accurate routing, evidence retrieval, response drafting, and commitment capture.

Teams involved: Global regulatory lead, regulatory medical writer, CMC regulatory affairs manager, regulatory operations/publishing manager, regulatory counsel, QA liaison, and program or asset team leader.

Key artifacts: Information request, RTQ, response plan, response document, deadline tracker, approval letter, and commitment extraction log.

Systems involved: Query tracker, document management system, RIM, submission archive, publishing tool, commitment register, and collaboration system.

Regulatory and control considerations: Health authority procedure timelines, response management SOP, PDUFA procedure clocks, and commitment-capture SOP, ICH M4.

Accountable roles: Global regulatory lead, regulatory medical writer, CMC regulatory affairs manager, and regulatory operations/publishing manager.

What AI helps with: Question classification, owner routing, retrieval-grounded generation, deadline forecasting, and commitment extraction can make response work more controlled. Contradiction detection can compare draft answers with prior dossier content, health authority feedback, and labeling positions.

What humans continue to own: The GRL owns response strategy, functional owners confirm technical answers, regulatory operations controls the submitted response, and regulatory counsel confirms high-risk language. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
Query intake and triage	IR and RTQ intake classification	Natural-language classification categorizes each health authority IR, RTQ, assessment question, or clarification request by domain, urgency, market, procedure, and response type. Deadline extraction identifies stated due dates and response windows, while rules-based timeline assessment calculates procedure-clock implications and escalation requirements
	Query metadata capture	Entity extraction captures product, application number, procedure, market, sequence, question identifier, review discipline, and authority contact from correspondence. RIM reconciliation flags mismatches between the query tracker, RIM record, and submission archive.
	Owner assignment and routing	Topic classification maps each question to clinical, nonclinical, CMC, labeling, device, biostatistics, regulatory operations, quality, or local affiliate owners. Workflow orchestration creates accountable response tasks and escalation paths for global regulatory lead review.
	Urgency and procedure-clock assessment	Deadline extraction and risk scoring compare query due dates, review clocks, clock-stop rules, planned submissions, and internal review cycles. Schedule-risk analysis identifies questions with insufficient preparation or review time and flags potential effects on submission and procedure timelines.
LOQ and multi-question coordination	LOQ response matrix creation	Information extraction converts a list of questions into a structured response matrix with question ID, topic, owner, source evidence, draft status, due date, review status, and publishing dependency. Workflow monitoring tracks progress against the response calendar.
LOQ and multi-question coordination	Cross-question consistency review	Semantic consistency checking compares draft answers across related questions, dossier sections, labeling positions, prior responses, and authority minutes.
Evidence retrieval and answer preparation	Source evidence retrieval	Semantic search retrieves relevant dossier sections, source reports, Module 3 records, study reports, prior responses, health authority minutes, labeling text, commitments, and registered details. Evidence ranking prioritizes approved sources most directly responsive to the authority question.
	Question-to-answer alignment	Natural-language inference checks whether the draft answer directly addresses the authority question and whether supporting evidence is sufficient. AI-assisted answer-evidence alignment flags evasive answers, missing data, incomplete rationale, and unsupported commitments.
	Response table and attachment mapping	Document classification maps each response to required tables, appendices, datasets, Module 3 extracts, labeling markups, technical reports, or administrative attachments. Completeness checking identifies missing or stale attachments before package review.
Cross-functional response drafting	Clinical response drafting	Retrieval-grounded generation drafts clinical response text from approved clinical study reports, integrated summaries, endpoint analyses, safety summaries, and prior authority feedback. Citation verification links each claim to controlled evidence and flags unsupported benefit-risk statements.
	CMC response drafting	Structured data extraction and retrieval-grounded generation draft CMC answers from specifications, validation reports, batch analyses, manufacturing process descriptions, stability summaries, and change-control records. Contradiction detection flags conflicts with Module 3, registered details, or prior commitments.
	Nonclinical response drafting	Evidence extraction retrieves pharmacology, toxicology, safety pharmacology, and PK data from approved nonclinical reports. Natural-language generation prepares concise answers while consistency checking compares the response with Module 2.4 and supporting study summaries.
	Labeling response drafting	Semantic difference compares proposed response wording with CCDS, USPI, SmPC, PIL, prior label negotiations, and local labeling positions. NLGdrafts label-related response text with deviation or rationale notes for labeling strategist review.
	Device response drafting	Document intelligence retrieves technical documentation, GSPR evidence, verification and validation reports, risk management files, clinical evaluation content, and Q-Sub feedback. Evidence mapping links each question to its supporting technical records, while retrieval-grounded generation prepares draft response text and flags areas with insufficient support.
Response review and approval	Functional owner review coordination	Workflow orchestration routes response drafts to clinical, CMC, nonclinical, labeling, device, quality, biostatistics, legal, or local affiliate reviewers. Status classification tracks review state, open comments, approval blockers, and late inputs.
	GRL position review	Cross-document consistency analysis compares the complete response package with the approved regulatory strategy, prior authority feedback, dossier content, labeling positions, registered details, and existing commitments
	Regulatory counsel escalation	Risk classification identifies answers involving legal interpretation, commitments, claims, comparative statements, market withdrawal risk, or dispute-sensitive language. Workflow routing escalates those items to regulatory counsel before final approval.
Publishing and submission handoff	Response package readiness check	Schema validation verifies required response sections, attachments, forms, metadata, owner approvals, document status, and publishing readiness. Completeness scoring prepares a go/no-go checklist for regulatory operations.
	Response sequence planning	Rules-based sequence-impact analysis recommends whether the approved response requires a new eCTD sequence, regional Module 1 update, attachment package, labeling markup, or administrative cover letter. Submission-calendar analysis identifies scheduling conflicts and dependencies across planned sequences that could affect submission timing.
	Response submission evidence retention	Evidence graph construction links the query, response plan, source evidence, draft versions, reviewer approvals, published sequence, and acknowledgment record. Audit-log generation preserves the response trail for inspection readiness.
Approval letter and commitment capture	Approval letter obligation extraction	Obligation extraction identifies PMRs, PMCs, specific obligations, due dates, evidence deliverables, milestone schedules, responsible owners, and impacted registrations from approval letters, opinion letters, or conditions documents. Entity linking connects each extracted obligation to the correct product, application, market, commitment-register entry, and RIM record.
	Commitment register update preparation	Structured data extraction converts approved obligation details into register fields such as commitment type, source, milestone, due date, owner, evidence requirement, market, application, and status. Data validation flags missing or inconsistent fields before GRL approval.
	Approval condition impact assessment	Knowledge-graph traversal links approval conditions to labeling, commitments, RIM registrations, submission calendars, evidence plans, and local affiliate actions. Rules-based impact mapping identifies the downstream workflows, accountable owners, required actions, and target dates resulting from the approval condition

Highest-value opportunities: IR and RTQ intake with response drafting support is high value because it combines recurring volume, strict clocks, and clear GRL review boundaries.

Example agentic workflow: RTQ intake-to-response packet workflow

Trigger: A CMC RTQ arrives for an in-review supplement.
Records retrieved: The agent retrieves the RTQ, the prior Module 3 section, batch records, the validation report, the related change-control record, previous authority correspondence, and the submission timeline.
Analysis prepared: The agent classifies the question by topic, urgency, evidence needs, owner, and response deadline, then compares the requested clarification against approved dossier content and source records.
Output prepared: The agent prepares a response plan, evidence-linked draft answer, source list, owner assignments, and unresolved exception notes.
Human checkpoint: The CMC regulatory affairs manager reviews the technical accuracy, and the global regulatory lead confirms the regulatory position.
Handoff: Regulatory operations publishes the approved response and updates the query tracker and submission record.

Function 8: Registration and license maintenance

Registration and license maintenance keep approved product registrations current as CMC changes, renewals, sunset clauses, annual reports, and global variations occur. It is the operating bridge between approved product reality, change control, and the regulatory record.

Teams involved: CMC regulatory affairs manager, global regulatory lead, regulatory affairs country manager, RIM data steward, regulatory operations manager, QA liaison, and regulatory counsel participate.

Key artifacts: EU eAF variation, Type IA, IB, or II assessment, US PAS, CBE-0, CBE-30, or annual report classification, renewal tracker, sunset-clause tracker, global change impact assessment, and PACMP record.

Systems involved: RIM, QMS change control, document management system, publishing tool, eAF portal, submission archive, and renewal tracker.

Regulatory and control considerations: 21 CFR 314.70, 21 CFR 314.81, ICH Q12, Variations Regulation (EC) 1234/2008, regional renewal rules, and internal change-control SOP.

Accountable roles: CMC regulatory affairs manager, global regulatory lead, regulatory affairs country manager, and RIM data steward.

What AI helps with: Rule-based classification, knowledge-graph traversal, and scenario simulation can connect a manufacturing or labeling change to impacted markets, supplement categories, variation types, and submission calendars. Deadline forecasting can identify renewal, sunset, and annual-report risk.

What humans continue to own: CMC RA and the GRL own variation classification, supplement category, filing strategy, and market-specific action. Local affiliates confirm country obligations and regulatory counsel confirms disputed interpretations. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
US post-approval change management	PAS classification	Policy-grounded classification compares a post-approval change against prior approval criteria under 21 CFR 314.70. Evidence extraction identifies affected manufacturing sites, specifications, process controls, labeling, validation evidence, and registered details that support a PAS recommendation.
	CBE-30 and CBE-0 classification	Rule-based classification evaluates whether the change may be implemented 30 days after FDA receipt or upon FDA receipt, based on approved change records, risk level, affected dossier sections, and supporting evidence. Precedent retrieval surfaces similar prior supplement decisions for CMC RA review.
	Annual report classification	Criteria-based classification evaluates whether a change has minimal potential to adversely affect product identity, strength, quality, purity, or potency and may therefore be reported in the next annual report Document intelligence extracts required change descriptions, implementation dates, affected sections, and supporting evidence for annual report preparation.
	21 CFR 314.81 annual report readiness assessment	Requirements-based completeness checking compares annual report content against reportable changes, open commitments, labeling updates, distribution status, and submission history. Completeness scoring flags missing change summaries, attachments, or cross-references.
Global CMC change control impact	Product-by-market impact assessment	Knowledge-graph traversal maps a global CMC change to affected products, markets, registrations, application numbers, dossier sections, manufacturing sites, specifications, and planned submissions. Entity resolution reconciles product and registration identifiers across QMS, RIM, DMS, and publishing systems.
	Registered detail comparison	Semantic comparison compares approved change-control details with registered information in each market, including manufacturing site, process description, batch size, specification, analytical method, container closure, storage condition, and shelf life. Anomaly detection helps to flag markets where registered details differ from the global baseline.
	PACMP and ICH Q12 alignment	Knowledge-graph traversal links the change to approved PACMPs, established conditions, reporting categories, prior commitments, and lifecycle management plans. Rule-based classification identifies whether the change follows an approved PACMP pathway or requires separate authority interaction.
	Regional action plan generation	Scenario simulation compares US, EU, Health Canada, PMDA, NMPA, and local market requirements, implementation timing, inventory needs, and planned sequence conflicts. Natural-language generation drafts a product-by-market regulatory action plan for GRL and CMC RA review.
Renewal management	Renewal calendar monitoring	Deadline forecasting tracks renewal dates, submission windows, document due dates, local affiliate inputs, and authority timelines. Risk scoring prioritizes renewals with missing evidence, late affiliate confirmation, or unresolved dossier updates.
	Renewal dossier readiness review	Document classification maps required renewal documents, product information, declarations, safety or benefit-risk summaries, manufacturing status, and local forms to the renewal checklist. Completeness scoring flags missing or outdated documents before local RA submission.
	Market status and sales evidence review	Entity extraction and anomaly detection compare market status, sales evidence, distribution records, and registration data.
Sunset clause monitoring	Sunset risk identification	Deadline forecasting and anomaly detection identify registrations at risk due to non-launch, supply interruption, inactive market status, or missing commercialization evidence. Market-impact mapping links risk records to products, local affiliates, renewal dates, and planned regulatory actions.
Sunset clause monitoring	Sunset mitigation planning	Retrieval-grounded generation drafts mitigation options such as affiliate confirmation, authority notification, renewal action, variation planning, or withdrawal assessment. Workflow orchestration routes mitigation tasks to local RA, GRL, and regulatory counsel where needed.
License maintenance governance	Registration record update after approval	RIM reconciliation compares approved variations, supplements, annual reports, renewals, and authority correspondence with registration records. Data validation flags missing approval dates, incorrect lifecycle status, outdated registered details, or incomplete market records.
	Local affiliate action tracking	Workflow orchestration converts global decisions into country-level actions for local RA teams. Status classification tracks affiliate actions across confirmation, submission, approval, implementation, and evidence retention.
	Inspection-ready maintenance evidence retention	Evidence graph construction links change control, classification rationale, variation or supplement package, authority correspondence, approval record, RIM update, and local implementation evidence. Audit-log generation preserves reviewer decisions, source documents, and final status.

Highest-value opportunities: Global CMC change impact assessment is high value because it prevents local license drift and missed variation obligations across markets.

Example agentic workflow: CMC change-to-global action plan workflow

Trigger: A global manufacturing-site change is approved in the QMS.
Records retrieved: The agent retrieves registered site details from RIM, the approved change-control record, affected Module 3 granules, PACMP commitments, prior related variations, and local variation rules.
Analysis prepared: The agent maps the manufacturing-site change to affected products, markets, registered details, dossier sections, variation categories, and submission timelines.
Output prepared: The agent drafts a product-by-market filing plan with proposed regulatory actions, evidence links, owner assignments, and unresolved classification exceptions.
Human checkpoint: The CMC regulatory affairs manager reviews and confirms the proposed classification and filing logic.
Handoff: Local regulatory affairs country managers validate market-specific actions and update local execution plans under the approved global strategy.

Function 9: Labeling and artwork regulatory management

Labeling regulatory management maintains alignment among core data sheets, regional product information, and local labels while ensuring compliance with approved regulatory positions, market-specific templates, and submission requirements. Its scope includes regulatory review and approval of artwork content.

Teams involved: Labeling strategist, global regulatory lead, regulatory affairs country manager, regulatory medical writer, regulatory counsel, QA liaison, and regulatory operations manager participate.

Key artifacts: Company core data sheet, CCDS deviation log, USPI, SPL XML file, SmPC, package leaflet, QRD template checklist, artwork regulatory review record, and local label approval tracker.

Systems involved: Labeling system, document management system, RIM, SPL authoring tool, submission archive, artwork workflow system, and local affiliate system.

Regulatory and control considerations: FDA SPL guidance,regional labeling procedures, company labeling SOP, approved CCDS governance, and local label deviation process.

Accountable roles: Labeling strategist, global regulatory lead, regulatory affairs country manager, regulatory counsel.

What AI helps with: Semantic comparison, structured label parsing, terminology mapping, and XML validation can compare core and local label text, identify deviations, and validate SPL or QRD structure. Retrieval-grounded generation can draft label-update rationale while preserving regulatory review boundaries.

What humans continue to own: The labeling strategist owns CCDS decisions and deviation acceptance; local RA confirms country label actions, and regulatory counsel reviews high-risk language. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
Core labeling management	CCDS creation	Retrieval-grounded generation drafts CCDS sections from approved labeling positions, clinical evidence, safety updates, efficacy data, benefit-risk rationale, and health authority feedback. Claim-evidence verification links each proposed label statement to approved source evidence for labeling strategist review.
	CCDS maintenance	Semantic comparison compares current CCDS text with new approved safety, efficacy, CMC, or authority-driven changes. Document differencing identifies text requiring addition, revision, or retirement, while change-impact mapping connects the approved changes with potentially affected local labels and markets.
	CCDS claim-evidence review	Evidence graph construction links indications, dosage, contraindications, warnings, adverse reactions, clinical study language, and special population statements to approved source documents. Contradiction detection flags label statements that conflict with dossier content, authority feedback, or prior approved wording.
	Labeling governance and approval tracking	Workflow orchestration routes CCDS updates through medical, safety, regulatory, legal, quality, and labeling review steps. Status classification tracks open comments, unresolved objections, approval blockers, and final labeling strategist disposition.
Local labeling management	CCDS-to-local-label impact assessment	Semantic comparison compares the approved CCDS change with USPI, SmPC, PIL, and local labels across markets. Impact classification identifies countries requiring submission, notification, implementation, justification, or no action.
	Local-label deviation tracking	Semantic comparison evaluates an approved CCDS change against the USPI, SmPC, PIL, and applicable local labels across markets. Classification separates justified local differences from unresolved deviations requiring labeling strategist or local RA review.
	Country action list preparation	Rules-based action mapping converts approved CCDS impacts into proposed country-level submissions, notifications, implementation activities, justifications, and evidence requirements. Deadline extraction maps implementation timelines, submission windows, and local authority requirements to each action.
	Local affiliate confirmation tracking	Status classification tracks affiliate review, local assessment, authority submission, approval, implementation, and evidence upload. Anomaly detection flags overdue confirmations, inconsistent implementation dates, or missing local-label evidence.
US labeling management	USPI preparation	Retrieval-grounded generation drafts or updates USPI sections from approved CCDS text, FDA feedback, clinical evidence, safety information, and prior label negotiations. Semantic consistency checking compares USPI language with approved claims, source evidence, and regulatory strategy.
	SPL XML preparation	Structured XML validation checks SPL header, body, identifiers, versioning, section codes, product data, establishment data, and required structured fields. Entity resolution reconciles SPL data with RIM, labeling system, and product master records.
	SPL validation error triage	Validation-error classification groups SPL errors and warnings by identifier, section, XML structure, vocabulary, versioning, product data, and missing field. Root-cause clustering groups related findings and prepares a prioritized correction queue for regulatory operations review.
	US label submission readiness assessment	Completeness scoring verifies approved USPI text, SPL XML, required forms, submission metadata, publishing status, and review approvals. Workflow monitoring flags unresolved labeling comments, missing approvals, or publishing blockers before submission.
Labeling variation and implementation	Labeling variation impact assessment	Rule-based classification maps labeling changes to required variation, supplement, notification, or annual report pathways by market. Knowledge-graph traversal links the label change to affected products, indications, strengths, presentations, and submission plans.
	Authority comment resolution	Semantic comparison compares authority comments, proposed label wording, company responses, CCDS text, and local label positions. Retrieval-grounded generation drafts response rationales and flags unresolved disagreement for labeling strategist or regulatory counsel review.
	Label implementation evidence retention	Evidence graph construction links CCDS approval, local label assessment, authority submission, approval, implementation date, final label, and reviewer decisions. Audit-log generation preserves the labeling evidence trail for inspection readiness.
Artwork regulatory review	Artwork text-to-label comparison	Computer vision OCRextracts text from artwork files, carton labels, container labels, IFUs, and packaging proofs. Semantic comparison checks extracted text against approved labeling, product information, dosage, warnings, storage conditions, and market-specific requirements.
	Artwork change regulatory disposition	Change classification identifies whether artwork changes are administrative, regulatory, safety-related, labeling-impacting, or market-specific. Exception scoring prepares a regulatory review disposition for local RA confirmation.
	Artwork approval evidence tracking	Workflow monitoring tracks artwork review, regulatory disposition, local affiliate approval, quality approval, final approved proof, and implementation evidence. Anomaly detection flags mismatched versions, missing approvals, or artwork released against outdated label text.

Highest-value opportunities: CCDS-to-local-label deviation tracking is high value because it turns a global label change into governed local actions without treating artwork production as the regulatory workflow.

Example agentic workflow: CCDS update-to-local deviation workflow

Trigger: A CCDS safety wording update is approved.
Records retrieved: The agent retrieves the updated CCDS, current local labels, USPI, SPL, SmPC, PIL text, approved safety evidence, and country-specific labeling requirements.
Analysis prepared: The agent compares the updated CCDS with current local labeling content, identifies impacted sections, classifies deviations, and maps required actions by market.
Output prepared: The agent prepares a deviation tracker, country action list, evidence links, implementation deadlines, and unresolved labeling exceptions.
Human checkpoint: The labeling strategist reviews and accepts the proposed deviation treatment.
Handoff: Local regulatory affairs teams confirm market-specific submissions, approvals, and implementation evidence.

Function 10: Post-marketing commitment and obligation management

Post-marketing commitment management turns approval conditions, PMRs, PMCs, specific obligations, and evidence milestones into a controlled closure system. It is adjacent to pharmacovigilance only where aggregate safety reports or safety deliverables must be submitted by RA after being authored in PV.

Teams involved: Global regulatory lead, program or asset team leader, regulatory operations manager, regulatory medical writer, RIM data steward, QA liaison, and regulatory affairs country manager participate.

Key artifacts: PMR or PMC tracking record, specific obligation register, approval letter, milestone schedule, evidence linkage map, closure dossier, annual status report, conditional approval status record.

Systems involved: Commitment register, RIM, document management system, submission archive, project management system, publishing tool, and PV system for submitted aggregate safety report references only.

Regulatory and control considerations: FDA PMR/PMC guidance, accelerated approval requirements,21 CFR 314.81, and commitment management SOP.

Accountable roles: Global regulatory lead, program or asset team leader, RIM data steward, and regulatory operations/publishing manager.

What AI helps with: Obligation extraction, deadline forecasting, evidence-link analysis, and closure-readiness scoring can keep commitments connected to deliverables and submission plans. Retrieval-grounded summarization can prepare status narratives from approved milestone evidence.

What humans continue to own: The GRL owns commitment interpretation and closure strategy, the asset team owns evidence delivery, regulatory operations controls submitted status reports. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
Commitment intake and registration	PMR and PMC identification from approval letters	Obligation extraction identifies PMRs, PMCs, study commitments, trial obligations, milestone dates, evidence deliverables, application numbers, and responsible owners from approval letters, action letters, meeting minutes, or authority correspondence. Entity linking maps each obligation to the correct product, application, market, and RIM record.
	PMR and PMC register maintenance	Structured data extraction converts commitment details into register fields such as commitment type, source, milestone, due date, evidence requirement, owner, status, and reporting obligation. Data validation flags missing dates, ambiguous wording, duplicate commitments, or mismatched application records.
	Commitment classification	Rule-based classification distinguishes PMRs, PMCs, accelerated approval requirements, post-authorization measures, specific obligations, voluntary commitments, and internal follow-up actions. Risk scoring prioritizes commitments by health authority importance, due date, evidence dependency, and market impact.
	Commitment owner assignment	Workflow orchestration assigns commitments to GRL, asset team, clinical, CMC, regulatory operations, PV, quality, or local affiliate owners. Dependency mapping identifies cross-functional inputs needed to meet each commitment milestone.
Specific obligation management	Conditional approval obligation tracking	Deadline forecasting tracks obligation milestones, submission windows, authority feedback points, and evidence readiness for conditional approvals. Dependency analysis identifies late evidence, missing owner input, and submission conflicts that require escalation.
	Specific obligation evidence plan review	Retrieval-grounded checklisting compares each obligation with the planned evidence package, study report, interim analysis, final report, registry data, CMC evidence, or post-authorization measure. Completeness scoring identifies gaps before evidence is due.
	Milestone and deliverable monitoring	Process mining tracks planned, pending, ongoing, delayed, submitted, fulfilled, released, or terminated milestone status across commitment registers, project plans, and submission archives. Anomaly detection flags inconsistent statuses or overdue deliverables.
	Authority communication planning	Deadline and event monitoring identifies milestones or exceptions that may require an authority status update, notification, clarification, or extension request. Retrieval-grounded generation drafts communication outlines for GRL review.
Commitment evidence management	Commitment-to-evidence linkage	Evidence graph construction links each commitment term to study protocols, final reports, interim analyses, CMC evidence, submissions, authority correspondence, reviewer decisions, and final disposition. Link analysis flags commitments without sufficient supporting evidence.
	Evidence package completeness review	Document classification maps each required evidence item to the corresponding commitment deliverable. Completeness checking flags missing reports, incomplete appendices, unapproved source documents, outdated evidence, or absent submission references.
	Closure dossier preparation	Retrieval-grounded generation drafts the closure rationale, evidence summary, milestone history, submission references, and authority correspondence summary from approved sources. Citation verification links every closure statement to retained evidence.
	Closure readiness scoring	Rule-based scoring compares commitment wording, evidence status, submission history, authority feedback, and final disposition criteria to determine whether the closure package is ready for GRL review. Exception classification identifies missing evidence, incomplete milestones, unresolved discrepancies, and matters requiring authority clarification before GRL review.
Annual status reporting	Annual PMR and PMC status report preparation	Natural-language generation drafts annual status narratives from approved register fields, milestone status, study progress, submission history, and evidence references. Status classification labels commitments as pending, ongoing, delayed, submitted, fulfilled, released, terminated, or otherwise requiring review.
	21 CFR 314.81 annual report cross-reference	Requirements-based reconciliation compares PMR and PMC status with the annual report calendar, application record, submitted sequences, and prior annual reports. Cross-reference validation flags missing or inconsistent commitment status references.
	Commitment delay and escalation review	Predictive analytics identifies commitments likely to miss milestone dates based on evidence readiness, owner status, study progress, and submission dependencies. Workflow orchestration routes identified risks, supporting evidence, required decisions, and proposed corrective actions to the GRL, asset team, and regulatory operations
	Submitted status evidence retention	Evidence graph construction links the annual status report, commitment register, submission sequence, acknowledgment, source evidence, reviewer approvals, and final submitted package. Audit-log generation preserves status-report evidence for inspection readiness.
Commitment governance	Commitment change and milestone update review	Semantic comparison compares proposed milestone changes, revised evidence plans, authority correspondence, and current register entries. Obligation impact analysis identifies whether a change affects due dates, evidence requirements, status reporting, or submission plans.
	Duplicate and conflicting commitment detection	Entity resolution matches product, application, market, authority, and commitment identifiers, while semantic similarity identifies potentially overlapping obligation language across PMR, PMC, specific-obligation, and internal-action records. Conflict detection flags duplicate obligations, inconsistent due dates, mismatched owners, and overlapping evidence requirements.
	Commitment dashboard and portfolio risk view	Knowledge-graph traversal connects commitments by product, application, market, authority, evidence type, due date, owner, and status. Risk scoring produces a portfolio view of delayed, high-impact, evidence-dependent, or inspection-sensitive commitments.
	Inspection-ready commitment trail	Audit-log generation preserves approval letters, commitment records, evidence plans, milestone updates, submitted reports, authority correspondence, closure decisions, and reviewer dispositions. Completeness scoring evaluates whether each commitment has a traceable end-to-end record from authority source through evidence delivery, reporting, and final disposition.

Highest-value opportunities: Commitment-to-evidence linkage is high value because commitment closure depends on traceable evidence, authority correspondence, and retained rationale.

Example agentic workflow: PMR milestone-to-closure dossier workflow

Trigger: A PMR milestone reaches its evidence due date.
Records retrieved: The agent retrieves the PMR commitment record, approved study report, milestone schedule, correspondence history, prior annual status reports, submission history, and related RIM records.
Analysis prepared: The agent maps the commitment wording to available evidence, milestone status, prior submissions, authority correspondence, and remaining closure requirements.
Output prepared: The agent drafts a closure evidence map, status narrative, source list, and any unresolved evidence exceptions.
Human checkpoint: The global regulatory lead reviews the evidence package and confirms closure readiness.
Handoff: Regulatory operations submits the approved report or closure package and updates the commitment register and submission archive.

Function 11: Regulatory information management and data governance

RIM and data standards turn registrations, product identifiers, submissions, commitments, labels, and device data into the enterprise regulatory system of record. This function is cross-cutting because every filing, variation, label action, and authority commitment depends on trusted regulatory master data.

Teams involved: RIM data steward, regulatory operations manager, global regulatory lead, regulatory affairs country managers, labeling strategist, CMC regulatory affairs manager, and QA liaison.

Key artifacts: RIM registration record, IDMP and SPOR data fields, xEVMPD submission record, GUDID data record,data quality exception log, and registration data stewardship dashboard.

Systems involved: RIM, IDMP or SPOR data hub, xEVMPD tool, GUDID, UDI system, labeling system, submission archive, and ERP or product master system.

Regulatory and control considerations: SPOR standards, xEVMPD requirements, 21 CFR Part 830, GUDID, and RIM data governance SOP.

Accountable roles: RIM data steward, regulatory operations/publishing manager, regulatory affairs country manager, and global regulatory lead.

What AI helps with: Entity resolution, data quality scoring, anomaly detection, and cross-system reconciliation can detect inconsistent product, substance, package, market, and UDI records. Controlled vocabulary mapping can prepare IDMP, SPOR, xEVMPD, and GUDID for steward review.

What humans continue to own: RIM data stewards own master-data corrections, local RA confirms market registration facts, and regulatory operations controls submitted data packages. AI scores, drafts, or prepares, but does not decide, approve, or attest.

Process	Sub-process	AI-enabled opportunities
RIM data governance	RIM registration record quality management	Entity resolution matches product, application, market, procedure, registration status, lifecycle event, submission date, approval date, and local affiliate data across RIM, submission archive, and local systems. Anomaly detection identifies inconsistent, missing, duplicate, or outdated values and prepares a data-quality exception log for RIM data steward review.
	Product and application identity reconciliation	Record linkage reconciles product names, strengths, dosage forms, presentations, application numbers, procedure numbers, device identifiers, market names, and sponsor entities across RIM, DMS, publishing, labeling, and product master systems. Duplicate detection flags conflicting or duplicate registration records.
	Lifecycle status consistency review	Status classification compares planned, submitted, approved, withdrawn, expired, renewed, suspended, or inactive statuses across RIM, submission archive, local affiliate records, and authority correspondence. Contradiction detection flags lifecycle states that do not match submitted or approved evidence.
	Registration date and milestone validation	Temporal anomaly detection identifies unexpected relationships among submission, approval, renewal, variation, implementation, sunset, and commitment dates. Deadline validation flags missing, impossible, stale, or inconsistent dates.
	RIM data-quality dashboarding	Knowledge-graph reconciliation links product, market, application, submission, variation, label, commitment, UDI, and xEVMPD records. Risk scoring produces a dashboard report of high-impact data-quality issues by product, market, owner, and downstream workflow impact.
IDMP and SPOR readiness assessment	Medicinal product data readiness assessment	AI-assisted controlled vocabulary mapping aligns product, pharmaceutical product, substance, dose form, route, strength, package, organization, and referential data to ISO IDMP and EMA SPOR expectations. Completeness scoring identifies missing or nonstandard fields for RIM data steward review.
	Substance and organization data alignment	Entity resolution maps substance identifiers, manufacturer names, MAH entities, sponsor entities, organizations, locations, and controlled terms across RIM, IDMP hub, SPOR services, product master, and CMC records. Anomaly detection flags inconsistent or nonstandard entity references.
	Dose form, route, strength, and package term mapping	Controlled-terminology mapping matches local and legacy dose-form, route, unit, strength, and packaging terms with applicable SPOR referentials and IDMP-aligned terminology. Semantic normalization prepares standardized values and flags terms requiring steward confirmation.
	IDMP readiness report preparation	Completeness scoring and validation rules assess product, substance, organization, referential, package, authorization, and lifecycle fields against the IDMP data model. Natural-language generation drafts a readiness report with gaps, owners, severity, and remediation actions.
xEVMPD maintenance	Authorized medicinal product data monitoring	Change detection compares authorized medicinal product data, variation events, registration updates, labeling changes, and market status changes to identify records that may require xEVMPD maintenance. Data validation prepares update candidates for regulatory affairs country manager review.
	xEVMPD update package preparation	Structured data extraction populates xEVMPD update fields from RIM registration records, approved variation data, product information, MAH details, and submission history. Schema validation identifies missing, inconsistent, or incorrectly formatted fields before authorized review and submission.
	xEVMPD data consistency review	Cross-system reconciliation compares xEVMPD records with RIM, approved SmPC or product information, variation approvals, and local market records. Contradiction detection identifies outdated product data, incorrect authorization status, or mismatched packaging details.
	xEVMPD submission evidence retention	Evidence graph construction links the xEVMPD update, triggering variation or registration event, source records, reviewer approval, submission confirmation, and final status. Audit-log generation preserves the maintenance trail for inspection readiness.
UDI data management	GUDID data preparation	Structured data extraction maps device master data, device identifier, labeler information, model, version, package levels, brand name, and market status to GUDID data requirements. Schema validation flags missing or inconsistent UDI fields before RIM data steward approval.
	Device identifier reconciliation	Entity resolution matches device identifiers, basic UDI-DI, UDI-DI, model numbers, catalog numbers, package levels, and registration status across RIM, UDI system, GUDID, EUDAMED, labeling, and product master systems. Anomaly detection flags conflicting device records.
	UDI submission status tracking	Event classification interprets GUDID submission statuses, acknowledgments, rejections, validation messages, and update confirmations. Workflow orchestration routes rejected or incomplete records to RIM, device regulatory, or local RA owners.
Enterprise regulatory master data	Registration master data governance	Knowledge-graph reconciliation connects registration records with product master data, labeling status, variations, submissions, commitments, UDI records, xEVMPD records, and authority correspondence. Lineage tracking shows which source record supports each enterprise regulatory data point.
	Product master and RIM alignment	Cross-system reconciliation compares product master data, ERP records, RIM registrations, labeling records, and submission history. Data validation flags mismatched product names, strengths, presentations, manufacturing sites, market status, or lifecycle events.
	Label, commitment, and registration linkage	Knowledge-graph traversal links approved labels, CCDS changes, local label actions, commitments, variations, and registration records. Impact analysis identifies where a label or commitment update requires a RIM record update or local affiliate action.
	Data stewardship workflow management	Workflow orchestration assigns data-quality exceptions to RIM data stewards, local affiliates, regulatory operations, labeling, or CMC RA owners. Status classification tracks open, corrected, approved, rejected, or escalated remediation actions.
	Inspection-ready regulatory data lineage	Evidence graph construction links every critical RIM data field to its source document, submission, authority correspondence, approval record, label record, UDI submission, xEVMPD update, or reviewer disposition. Audit-log generation preserves the data lineage needed for inspection readiness.

Highest-value opportunities: RIM data quality monitoring is high value because weak registration data undermines every submission plan, variation assessment, label action, and commitment report.

Example agentic workflow: RIM data quality-to-stewardship workflow

Trigger: A monthly RIM data-quality run identifies conflicting market status and UDI records for an EU device.
Records retrieved: The agent retrieves the RIM registration record, EUDAMED device record, GUDID record, UDI system data, product master record, local affiliate market status, and related submission history.
Analysis prepared: The agent reconciles device identifiers, market status, registration details, UDI data, and product master fields across systems.
Output prepared: The agent prepares a data-quality exception log, suspected root cause, proposed corrections, evidence links, and steward action assignments.
Human checkpoint: The RIM data steward reviews and confirms the proposed corrections.
Handoff: Local regulatory affairs validates market facts, and approved corrections are updated under the RIM data governance workflow.

Accelerate AI Solutions Development

Build fully functional solutions from your high-value use cases, based on specific operational needs and enterprise context.

Book a Customized Demo

High-value AI use cases in regulatory affairs

High-value AI use cases in regulatory affairs are the ones that improve decision readiness without weakening regulatory accountability. They typically involve recurring work, reliable source artifacts, clear reviewer ownership, regulatory consequences, and a need to retain evidence for inspection or audit.

The goal is not to transfer authority to a model. It is to help regulatory teams prepare more complete review packets, surface gaps earlier, coordinate cross-functional inputs, and preserve a clearer decision trail for accountable RA roles.

Use case	Function	How AI creates high-value impact
Guidance impact triage	Regulatory intelligence and surveillance	AI reduces the time between a health authority update and a portfolio action by identifying affected products, markets, dossier sections, commitments, and planned sequences. This gives the GRL a cited, consolidated impact view of affected products, markets, dossier sections, and commitments without having to reconcile information across RIM, DMS, publishing, and commitment records manually.
Designation strategy evidence pack	Regulatory strategy development	AI improves designation planning by comparing the product’s evidence against orphan, Fast Track, Breakthrough Therapy, or other expedited-program criteria. It helps the GRL see eligibility strengths, evidence gaps, precedent alignment, and open risks before deciding whether to pursue a designation.
Health authority meeting package preparation	Health authority interaction management	AI reduces package rework by checking whether questions, company positions, evidence, and attachments are complete and aligned before submission. It helps the GRL and regulatory medical writer focus on the strength of the regulatory argument rather than assembling and cross-checking the package manually.
eCTD gap analysis	Submission planning and dossier management	AI helps prevent late submission blockers by comparing the planned dossier against CTD structure, regional Module 1 requirements, forms, source documents, and granule ownership. Regulatory operations teams receive a prioritized gap report early to address missing content before it delays authoring or publishing.
Module 2 and Module 3 drafting support	Dossier authoring	AI accelerates controlled drafting by generating reviewable narrative sections from approved source reports and linking claims to evidence. It reduces unsupported statements, inconsistent terminology, and cross-section conflicts before regulatory writers and CMC RA owners review the content.
Validation error triage	Publishing and submission operations	AI shortens publishing correction cycles by grouping validation errors by root cause, affected file, metadata issue, lifecycle operator, hyperlink, or regional requirement. Regulatory operations teams can focus on the highest-risk fixes before sequence release.
RTQ and IR response coordination	Health authority query and response management	AI helps protect response timelines by classifying questions, assigning owners, extracting due dates, retrieving source evidence, and preparing draft response packets. This reduces coordination delays and gives the GRL a consolidated view of the supporting evidence, open issues, and exceptions that require review before the response is finalized.
Variation and supplement classification	Registration and license maintenance	AI reduces classification risk by comparing approved change controls with registered details, prior decisions, and US supplement categories. CMC RA receives a cited recommendation that exposes assumptions, affected markets, and disputed classification points before filing decisions are made.
CCDS-to-local-label deviation tracking	Labeling and artwork regulatory management	AI improves labeling control by identifying where local labels, USPI, SPL, SmPC, or PIL text diverges from an approved CCDS update. Labeling teams can prioritize markets requiring submission, justification, correction, or local affiliate confirmation.
PMR and PMC closure tracking	Post-marketing commitment and obligation management	AI reduces missed commitment risk by linking each PMR or PMC to due dates, evidence deliverables, source documents, prior status reports, and authority correspondence. The GRL receives a clearer closure-readiness view before annual reporting or commitment closure.
RIM data quality monitoring	Regulatory information management and data standards management	AI improves trust in regulatory master data by detecting inconsistent product, market, application, lifecycle, IDMP, xEVMPD, GUDID, or EUDAMED records. RIM stewards can correct high-impact data issues before they affect submissions, labeling, commitments, or enterprise reporting.

A use case earns high-value status when it produces a bounded artifact, preserves a named review boundary, and creates evidence that downstream regulatory, publishing, labeling, local affiliate, or quality teams can use.

How agentic AI works in regulatory affairs workflows

An agentic workflow coordinates retrieval, deterministic checks, model-based interpretation, business rules, and human checkpoints across a longer regulatory task. It should write evidence and state back to the appropriate system of record, while filing, labeling, commitment, and strategy decisions remain with accountable RA roles.

Here are some examples:

Example 1: Guideline revision to variation plan

Agent role: Turn a health authority guideline revision into a product-by-market variation plan ready for regulatory review.
Starting artifacts: FDA publishes updated guidance on nitrosamine impurity limits with a defined implementation timeline.
Workflow:
- The agent aggregates affected US registrations and dossier sections from RIM.
- It retrieves current Module 3.2.S and 3.2.P specifications from the document management system.
- It checks in-flight FDA submission sequences from the publishing tool.
- It identifies open postmarketing commitment or requirement entries related to impurity commitments.
- It retrieves the regulatory intelligence SOP and FDA change-category classification playbook.
- It maps the FDA guidance update to affected products, applications, and dossier granules.
- It prepares an impact memo, supplement or amendment strategy, draft eCTD content plans, and FDA submission calendar overlay.

Exception handling: Disputed applicability, missing registered details, or conflicting FDA reporting-category interpretations are flagged in the packet rather than resolved silently.

Human checkpoint: The regulatory intelligence analyst confirms applicability, then the US regulatory lead approves the supplement or amendment strategy or escalates disputed classifications to the head of regulatory affairs.

Output and audit evidence: Approved plans generate CMC authoring tasks, RIM planned-submission updates, postmarketing commitment or requirement annotations, and an intelligence-to-action evidence packet.

Example 2: RTQ response packet workflow

Agent role: Prepare a deadline-controlled response package for a health authority query.
Starting artifacts: An FDA RTQ arrives for an in-review CMC supplement and requests clarification on specification acceptance criteria.
Workflow:
- The agent classifies the question by topic, urgency, market, procedure, and response owner.
- It extracts the response deadline and any procedure-clock implications.
- It retrieves the prior Module 3 section.
- It retrieves the validation report, batch data summary, approved specification, and prior correspondence.
- It compares the requested clarification against approved dossier content and source evidence.
- It drafts a response plan and evidence-linked answer for reviewer approval.
Exception handling: Missing source data, conflicting specifications, or unsupported claims stop the draft at an exception state and route the issue to the CMC RA owner.
Human checkpoint: The CMC regulatory affairs manager confirms technical content, the GRL approves the regulatory position, and regulatory operations controls final publishing.
Output and audit evidence: The response package, source list, assumptions, reviewer actions and published sequence reference are retained in RIM and the submission archive.

Example 3: eCTD validation and ACK reconciliation workflow

Agent role: Move a validated sequence from publishing readiness to acknowledged submission status.
Starting artifacts: A compiled eCTD sequence for an NDA supplement has a validation report with warnings and a planned FDA ESG submission date.
Workflow:
- The agent classifies validation warnings by severity, affected file, metadata issue, lifecycle operator, hyperlink, or regional requirement.
- It checks lifecycle operators against the prior sequence history.
- It verifies regional Module 1 metadata, bookmarks, hyperlinks, and application metadata.
- It prepares a submission release checklist with open warnings and evidence links.
- After human release, it monitors ACK messages from the submission gateway.
- It reconciles ACK status with RIM and the submission archive.
Exception handling: Critical validation errors, unexpected ACK status, missing ACK messages, or mismatched application identifiers create a regulatory operations exception.
Human checkpoint: The regulatory operations/publishing manager approves release and confirms final ACK disposition.
Output and audit evidence: The validation report, release checklist, ACK log, sequence status and reviewer identity are written to the submission archive and RIM.

Example 4: PMR closure evidence workflow

Agent role: Prepare a closure dossier for a post-marketing requirement or commitment.
Starting artifacts: A PMR milestone reaches its evidence due date and the asset team marks the supporting study report as approved.
Workflow:
- The agent retrieves the approval letter and PMR register entry.
- It retrieves the study report, prior annual status reports, authority correspondence, and submission history.
- It maps each commitment term to the available evidence and milestone status.
- It identifies missing evidence, unresolved authority questions, or closure risks.
- It builds an evidence map for the closure package.
- It drafts the closure status narrative for GRL review.
Exception handling: Incomplete milestone evidence, ambiguous commitment wording, missing submission references, or conflicts with prior status reports are routed to the GRL.
Human checkpoint: The global regulatory lead confirms closure readiness and regulatory operations teams submit the approved status or closure package.
Output and audit evidence: The commitment register, RIM record, source evidence list, reviewer disposition, and submitted package reference are retained for inspection readiness.

How to prioritize AI use cases in regulatory affairs

Prioritization should begin with the regulatory sub-process, not the AI platform. The strongest first use cases are recurring, artifact-rich, and governed by a clear review boundary. They should produce a draft, exception list, evidence packet, or readiness report that a named RA role can review before any filing, label, commitment, or RIM record is affected.

Good starting points also have a credible risk-reduction story. They help reduce submission delays, query-response bottlenecks, commitment tracking gaps, publishing rework, labeling inconsistencies, or RIM data-quality issues.

Criterion	What to ask
Volume and frequency	Does this sub-process recur often enough across submissions, variations, queries, labels, or RIM records for AI support to reduce manual evidence preparation at scale?
Artifact availability	Are the needed source artifacts available in usable systems with reliable product, application, market, document, sequence, commitment, and identifier data?
Review boundary	Can a defined RA role confirm the AI output before it affects a filing strategy, submission release, health authority commitment, label position, variation classification, or RIM master record?
Blast radius	If the output is wrong, is the impact limited to a draft, exception queue, gap report, or recommendation rather than a submitted sequence, incorrect label, missed commitment, or inaccurate registration record?
Business impact	Can the function tie the use case to credible outcomes such as fewer returned packages, lower publishing rework, faster query coordination, cleaner RIM data, reduced missed commitments, or improved inspection readiness?

The classic failure patterns are misaligned scope, missing data, bypassed governance, and premature quantified savings. Strong starting points are guidance impact triage, dossier gap analysis, validation error triage, RTQ routing, CCDS deviation tracking, PMR register maintenance, and RIM data quality monitoring.

Governance, risk, and responsible AI in regulatory affairs

AI in regulatory affairs must be governed around the same principles that govern regulatory work itself: source control, reviewer accountability, traceability, data protection, and inspection readiness. Because AI outputs can influence filing strategy, submission content, health authority responses, labeling decisions, commitments, and RIM records, every use case needs clear limits on what the system may prepare and what only an accountable regulatory role may approve.

Human-in-the-loop (HITL) oversight

Every use case needs a named accountable reviewer and a stop condition. AI may draft meeting packages, variation recommendations, response text, label deviation lists, validation fix queues and commitment logs, but filing decisions, submission release, label acceptance and regulatory attestations remain human actions.

Regulatory and standards alignment

AI controls should be mapped to the regulatory stack that governs the work, including ICH M4 and M8 for CTD and eCTD structure, ICH Q12 for post-approval change management, FDA meeting and eCTD expectations, QRD templates, SPL guidance, IDMP, UDI, GUDID requirements. NIST AI RMF can support governance, measurement, monitoring and risk management for the AI layer.

Bias mitigation and evidence retention

Bias can enter through precedent selection, language-country imbalance, historical reviewer behavior, incomplete public data and over-weighting one authority position. Each recommendation should retain source artifacts, retrieval timestamp, model and prompt version, confidence, assumptions, exceptions and reviewer disposition.

Key governance requirements

The use-case inventory should separate low-risk summarization from higher-risk classification and recommendation. Variation classification, label deviation acceptance, commitment closure and submission release need risk tiering, approval gates, escalation paths and audit trails.

Design principles

Ground AI outputs in approved, authoritative sources and enforce role-based, least-privilege access. Use deterministic validation, schema checks, lifecycle rules, and controlled vocabularies where applicable. Configure agent permissions so consequential actions—including submission release, regulatory approval, attestation, and changes to authoritative RIM records—cannot proceed without explicit confirmation from an authorized reviewer.

Traceability and data security

The system should retain prompts, sources, model version, deterministic tool version, reviewer action, approval trail, and system updates. Regulatory records may include confidential product strategy, clinical data, CMC details, device technical documentation, personal data, and commercially sensitive launch plans, so retrieval indexes and logs must inherit access controls.

Accelerate AI Solutions Development

Build fully functional solutions from your high-value use cases, based on specific operational needs and enterprise context.

Book a Customized Demo

How ZBrain operationalizes AI use cases in regulatory affairs

Identifying use cases in regulatory affairs is only the first step.Regulatory affairs teamsneed a controlled way to design, build, validate, deploy, govern, and scale AI workflows across regulatory intelligence, strategy development, health authority interactions, submission planning, dossier authoring, publishing, query response, license maintenance, labeling, commitment management, and RIM data governance.

This is where ZBrain helps.

ZBrain is an end-to-end AI enablement platform that supports this lifecycle through four connected stages: ZBrain Analyzer, ZBrain Design, ZBrain Solution Builder, and ZBrain Governance. The platform provides a governed path from use-case analysis to deployed agentic workflows while maintaining policies, permissions, approval points, monitoring, and runtime evidence.

ZBrain Analyzer

ZBrain Analyzer helps teams examine selected regulatory affairs processes, identify AI opportunities, and document the business context, systems, data, artifacts, roles, controls, and review requirements needed to evaluate each use case.

ZBrain Design

ZBrain Design creates a build-ready technical design for the selected use case. It generates the business requirements document, functional requirements, user journeys, architecture, workflow logic, data specifications, integration context, and governance considerations needed before development begins.

ZBrain Solution Builder

ZBrain Solution Builder enables teams to create, configure, and validate governed AI workflows for regulatory affairs processes based on the technical design developed in ZBrain Design. It supports testing across routine, exception, deadline-driven, and control scenarios before deployment.

ZBrain Governance

ZBrain Governance applies policies, access controls, human approval requirements, monitoring, and traceability throughout workflow execution. It provides guardrails, approval gates, escalation controls, kill switches, and audit trails to help organizations maintain oversight of AI outputs, reviewer actions, exceptions, and authorized system updates.

Future of AI in regulatory affairs

The near-term future is a federated regulatory operations layer that can reason across RIM, DMS, publishing, labeling, QMS, commitment registers, UDI systems, health authority portals and submission archives while respecting the authority of each platform. Regulatory identity graphs will matter because filings, labels, commitments and registrations depend on relationships among products, applications, markets, indications, documents, sequences, identifiers and obligations.

Long-horizon agents will move beyond one-time drafting. They will monitor a guidance event through impact assessment, variation planning, authoring, publishing, ACK monitoring, local affiliate action, commitment annotation and evidence retention. Their value will come from maintaining context across weeks or months, with each risk-bearing transition gated by a named regulatory owner.

Model capability will improve, but the durable advantage will come from workflow design. Organizations that define clean regulatory master data, controlled source repositories, explicit review boundaries, submission lifecycle rules, variation playbooks and retained evidence will be able to adopt new models without rebuilding the operating system around them.

The future of AI in regulatory affairs depends on governed workflow design, not only better models. The winners will be teams that can turn health authority signals and portfolio data into review-ready action while preserving accountability for every filing, label, commitment and registration record.

Endnote

AI in regulatory affairs delivers the most value when it strengthens controlled regulatory work rather than attempting to replace regulatory judgment. Its role is to connect approved evidence, prepare review-ready outputs, coordinate workflows, surface exceptions, and preserve the traceability required for accountable decision-making.

Across regulatory intelligence, submissions, publishing, labeling, license maintenance, commitment management, and RIM, AI can help teams prepare impact assessments, evidence packs, dossier drafts, validation queues, response packets, variation plans, deviation trackers, closure dossiers, and data-quality exceptions. The underlying regulatory systems and records, including RIM, eCTD sequences, health authority correspondence, labeling records, source documents, commitments, and submission archives, must remain authoritative.

Organizations should therefore begin with bounded, evidence-rich sub-processes where AI produces drafts, recommendations, exception lists, or review packets for named regulatory owners. As source grounding, identity resolution, exception handling, approval controls, and auditability mature, the same governed approach can extend across broader regulatory workflows without weakening accountability.

ZBrain supports this progression from use-case identification and technical design through solution development, validation, deployment, and governance, helping regulatory teams operationalize AI while keeping consequential regulatory decisions under human control.

Design governed AI-powered regulatory workflows that connect regulatory intelligence, submission planning, dossier authoring, publishing, labeling, commitment management, and RIM data governance. Contact the ZBrain team today.

Author’s Bio

Akash Takyar

CEO LeewayHertz

Akash Takyar is the founder and CEO of LeewayHertz. With a proven track record of conceptualizing and architecting 100+ user-centric and scalable solutions for startups and enterprises, he brings a deep understanding of both technical and user experience aspects.
Akash's ability to build enterprise-grade technology solutions has garnered the trust of over 30 Fortune 500 companies, including Siemens, 3M, P&G, and Hershey's. Akash is an early adopter of new technology, a passionate technology enthusiast, and an investor in AI and IoT startups.

Write to Akash

Related Products

AI Agent

Discover the right AI agent for your use case! Explore our extensive range of AI agents tailored to tackle specific challenges.

Explore AI Agents

Start a conversation by filling the form

Once you let us know your requirement, our technical expert will schedule a call and discuss your idea in detail post sign of an NDA.
All information will be kept confidential.

Phone

This field is for validation purposes and should be left unchanged.

This field is hidden when viewing the form

OID

This field is hidden when viewing the form

Campaign ID

This field is hidden when viewing the form

Source

This field is hidden when viewing the form

Lead Source Description

First Name(Required)

Last Name(Required)

Company Email(Required)

Company Name(Required)

Job Title(Required)

Phone

Country(Required)

Select a state/province(Required)

Comments(Required)

Checkbox(Required)

I agree to the Terms of use and Privacy policy.

FAQs

What is AI in regulatory affairs?

AI in regulatory affairs is the use of AI capabilities such as document intelligence, retrieval-grounded generation, classification, anomaly detection, graph analytics, and agentic workflow orchestration to support regulated RA work. It can help teams monitor health authority updates, prepare submission plans, draft evidence-linked dossier content, triage publishing issues, coordinate query responses, track license maintenance actions, manage labeling changes, monitor commitments, and improve RIM data quality.

Its role is to prepare evidence, drafts, exception lists, and review packets for accountable regulatory roles. It does not replace human authority for filing strategy, submission release, health authority commitments, label decisions, or regulatory attestations.

Which AI use cases are most vital in regulatory affairs?

The most vital AI use cases in regulatory affairs are those that reduce submission risk, improve evidence readiness, and strengthen traceability across regulated workflows. They are most valuable when they support recurring, artifact-heavy work while keeping final decisions with accountable RA roles.

Regulatory intelligence and strategy: guidance impact triage, precedent analysis, designation evidence packs and global submission sequencing.
Submissions and publishing: eCTD content planning, dossier gap analysis, source readiness tracking, validation error triage and ACK monitoring.
Health authority interactions and queries: briefing package preparation, minutes reconciliation, IR or RTQ routing, response drafting and commitment extraction.
Maintenance and labeling: variation classification, supplement category support, CCDS-to-local-label deviation tracking, SPL and QRD checks, and artwork regulatory review.
Commitments and RIM: PMR or PMC register maintenance, closure dossier preparation, IDMP or SPOR readiness, xEVMPD maintenance, UDI data checks and RIM data-quality monitoring.

Can AI submit filings or approve regulatory positions autonomously?

It should not be assigned autonomous authority to submit, approve or attest. AI may prepare a release checklist, classify validation errors, draft a recommendation, route a packet and monitor acknowledgments. A named authorized regulatory owner should confirm filing intent, submission release, label position, commitment status and RIM updates.

What systems and data are needed for AI in regulatory affairs?

A strong AI foundation in regulatory affairs requires access to the systems where regulatory artifacts, lifecycle events, authority correspondence, and product-market records are created and maintained. The most important requirement is not having every record in one platform, but having reliable identifiers across systems.

Core systems and data typically include RIM records, document management systems, publishing tools, submission archives, health authority correspondence, labeling systems, commitment registers, QMS change records, UDI systems, GUDID data, xEVMPD records, IDMP/SPOR data, product master data, and local affiliate registration data. Common identifiers for product, application, market, submission sequence, document, label, commitment, variation, device, and registration status are essential for reliable retrieval, reconciliation, and auditability.

Where should regulatory affairs teams begin with AI?

Organizations should begin with one bounded sub-process and one named reviewer. Practical starting points include regulatory intelligence triage, eCTD gap analysis, validation error clustering, RTQ routing, meeting minutes reconciliation, CCDS deviation tracking, PMR register maintenance and RIM data-quality exception management. Run in read-only or draft mode first, then allow controlled writeback after reviewer correction patterns and audit logging are reliable.

How should AI handle eCTD validation or variation classification?

For eCTD work, AI should classify validator findings, identify root causes and prepare a fix queue, while the publishing manager confirms sequence release. For variation classification, AI should retrieve approved playbooks, registered details, change records and 21 CFR 314.70 categories, then propose a cited recommendation. The CMC RA owner or GRL confirms the classification.

How does ZBrain support AI in regulatory affairs?

ZBrain supports AI in regulatory affairs by helping teams move from use-case identification to governed workflow deployment. It provides a controlled path to analyze regulatory processes, design AI workflows, build and validate agentic solutions, and govern execution across regulatory intelligence, submission planning, dossier authoring, publishing, labeling, commitment management, health authority interactions, and RIM data governance.

This is performed through following connected modules-

ZBrain Analyzerhelps assess regulatory affairs processes, identify AI opportunities, and document the artifacts, systems, roles, controls, and review requirements for each use case.
ZBrain Design converts selected use cases into build-ready technical designs, including workflow logic, data requirements, integration context, user journeys, exception paths, and governance considerations.
ZBrain Solution Builder enables teams to create, configure, and test governed AI workflows across routine, exception, deadline-driven, and control scenarios.
ZBrain Governance applies policies, permissions, approval gates, monitoring, traceability, escalation controls, and audit trails so AI outputs remain reviewable and accountable.

AI in regulatory affairs: Transforming regulatory intelligence, submission planning, authoring, and commitment management

How AI is transforming regulatory affairs operations

Why AI use cases in regulatory affairs must be mapped at the sub-process level

Build governed AI workflows across field service operations

Regulatory affairs operating model and AI opportunity mapping across regulatory affairs processes

Function 1: Regulatory intelligence and surveillance

Function 2: Regulatory strategy development

Function 3: Health authority interaction management

Function 4: Submission planning and dossier management

Function 5: Dossier authoring

Accelerate AI Solutions Development

Function 6: Publishing and submission operations

Function 7: Health authority query and response management

Function 8: Registration and license maintenance

Function 9: Labeling and artwork regulatory management

Function 10: Post-marketing commitment and obligation management

Function 11: Regulatory information management and data governance

Accelerate AI Solutions Development

High-value AI use cases in regulatory affairs

How agentic AI works in regulatory affairs workflows

Example 1: Guideline revision to variation plan

Example 2: RTQ response packet workflow

Example 3: eCTD validation and ACK reconciliation workflow

Example 4: PMR closure evidence workflow

How to prioritize AI use cases in regulatory affairs

Governance, risk, and responsible AI in regulatory affairs

Human-in-the-loop (HITL) oversight

Regulatory and standards alignment

Bias mitigation and evidence retention

Key governance requirements

Design principles

Traceability and data security

Accelerate AI Solutions Development

How ZBrain operationalizes AI use cases in regulatory affairs

ZBrain Analyzer

ZBrain Design

ZBrain Solution Builder

ZBrain Governance

Future of AI in regulatory affairs

Endnote

Author’s Bio

Related Products

AI Agent

Start a conversation by filling the form

FAQs

What is AI in regulatory affairs?

Which AI use cases are most vital in regulatory affairs?

Can AI submit filings or approve regulatory positions autonomously?

What systems and data are needed for AI in regulatory affairs?

Where should regulatory affairs teams begin with AI?

How should AI handle eCTD validation or variation classification?

How does ZBrain support AI in regulatory affairs?

Insights

AI in Engineering Change Management: Enterprise Use Cases Across Operating Model

AI use cases and applications in private equity & principal investment

AI-powered dynamic pricing solutions: Use cases, architecture and future trends

Related Functional Agents

Sales AI Agents

Legal AI Agents

HR AI Agents